Solventum (SOLV) 10-K 28 Feb 25 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Feb. 21, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-41968
Entity Registrant Name	SOLVENTUM CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	92-2008841
Entity Address, Address Line One	3M Center, Building 275-6W
Entity Address, Address Line Two	2510 Conway Avenue East
Entity Address, City or Town	Maplewood
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55144
City Area Code	651
Local Phone Number	733-1110
Title of 12(b) Security	Common Stock, Par Value $0.01 Per Share
Trading Symbol	SOLV
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 9.1
Entity Common Stock, Shares Outstanding		172,990,490
Documents Incorporated by Reference	Parts of the Company's definitive proxy statement (to be filed pursuant to Regulation 14A within 120 days after the Registrant's fiscal year-end of December 31 ,2024) for its annual meeting to be held on April 30, 2025, are incorporated by reference in this Form 10-K in response to Part III, Items 10, 11, 12, 13 and 14.
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Central Index Key	0001964738

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Auditor [Abstract]
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Minneapolis, Minnesota

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Total net sales	$ 8,254	$ 8,197	$ 8,130
Gross profit	4,593	4,693	4,695
Selling, general and administrative expenses	2,782	2,243	2,235
Research and development expenses	775	758	767
Operating income	1,036	1,692	1,693
Interest expense, net	367	0	0
Other expense (income), net	64	25	1
Income before income taxes	605	1,667	1,692
Provision for income taxes	127	321	349
Net income	$ 479	$ 1,346	$ 1,343
Earnings per share:
Basic earnings per share (in dollars per share)	$ 2.77	$ 7.79	$ 7.78
Diluted earnings per share (in dollars per share)	$ 2.76	$ 7.79	$ 7.78
Weighted-average number of shares outstanding:
Basic (in shares)	173.2	172.7	172.7
Diluted (in shares)	173.7	172.7	172.7
Cost of product
Total net sales	$ 6,348	$ 6,296	$ 6,300
Cost of sales	3,172	3,023	2,953
Cost of software and rentals
Total net sales	1,906	1,901	1,830
Cost of sales	$ 489	$ 481	$ 482

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 479	$ 1,346	$ 1,343
Other comprehensive income (loss), net of tax:
Cumulative translation adjustment	(203)	157	(331)
Defined benefit pension	(5)	(33)	34
Cash flow hedging instruments	20	0	0
Total other comprehensive income (loss), net of tax	(188)	124	(297)
Comprehensive income	$ 291	$ 1,470	$ 1,046

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 762	$ 194
Accounts receivable — net of allowances of $86 and $82	1,044	1,313
Due from related parties	185	0
Inventories
Finished goods	539	453
Work in process	190	171
Raw materials and supplies	236	233
Total inventories	965	857
Other current assets	293	155
Total current assets	3,249	2,519
Property, plant and equipment — net	1,622	1,457
Goodwill	6,377	6,535
Intangible assets — net	2,544	2,902
Other assets	665	530
Total assets	14,457	13,943
Current liabilities
Short-term borrowings and current portion of long-term debt	200	0
Accounts payable	618	477
Due to related parties	272	0
Unearned revenue	572	574
Other current liabilities	1,041	677
Total current liabilities	2,703	1,728
Long-term debt	7,810	0
Pension and postretirement benefits	350	166
Deferred income taxes	225	231
Other liabilities	410	152
Total liabilities	11,498	2,277
Commitments and contingencies (Note 11)
Equity
Common stock, par value $0.01 per share, 750,000,000 shares authorized Shares issued and outstanding - December 31, 2024: 172,785,606 Shares issued and outstanding - December 31, 2023: 0	2	0
Additional paid-in-capital	3,771	0
Retained earnings	242	0
Net parent investment	0	12,003
Accumulated other comprehensive income (loss)	(1,056)	(337)
Total equity	2,959	11,666
Total liabilities and equity	$ 14,457	$ 13,943

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Net of allowances	$ 86	$ 82
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock authorized (in shares)	750,000,000	750,000,000
Common stock issued (in shares)	172,785,606	0
Common stock outstanding (in shares)	172,785,606	0

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In-Capital	Retained Earnings	Net Parent Investment	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2021		0
Beginning balance at Dec. 31, 2021	$ 12,059	$ 0	$ 0	$ 0	$ 12,259	$ (200)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,343				1,343
Other comprehensive income (loss), net of tax:
Cumulative translation adjustment	(331)					(331)
Defined benefit pension	34					34
Cash flow hedging	0
Total other comprehensive income (loss), net of tax	(297)					(297)
Net transfers to 3M	(1,363)				(1,363)
Ending balance (in shares) at Dec. 31, 2022		0
Ending balance at Dec. 31, 2022	11,742	$ 0	0	0	12,239	(497)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,346				1,346
Other comprehensive income (loss), net of tax:
Cumulative translation adjustment	157					157
Defined benefit pension	(33)					(33)
Cash flow hedging	0
Total other comprehensive income (loss), net of tax	124					124
Net transfers to 3M	$ (1,546)				(1,582)	36
Ending balance (in shares) at Dec. 31, 2023	0	0
Ending balance at Dec. 31, 2023	$ 11,666	$ 0	0	0	12,003	(337)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	479			242	237
Other comprehensive income (loss), net of tax:
Cumulative translation adjustment	(203)					(203)
Defined benefit pension	(5)					(5)
Cash flow hedging	20					20
Total other comprehensive income (loss), net of tax	(188)					(188)
Net transfers to 3M	(9,102)				(8,571)	(531)
Stock-based compensation	108		108
Common stock for tax withholding obligations	(4)		(4)
Issuance of common stock in connection with Spin-Off and reclassification of net parent investment (in shares)		173,000,000
Issuance of common stock in connection with Spin-Off and reclassification of net parent investment	$ 0	$ 2	3,667		(3,669)
Ending balance (in shares) at Dec. 31, 2024	172,785,606	173,000,000
Ending balance at Dec. 31, 2024	$ 2,959	$ 2	3,771	242	0	(1,056)
Beginning balance (in shares) at Mar. 31, 2024	0
Other comprehensive income (loss), net of tax:
Issuance of common stock in connection with Spin-Off and reclassification of net parent investment (in shares)	172,709,505
Ending balance (in shares) at Apr. 01, 2024	172,709,505
Beginning balance (in shares) at Mar. 31, 2024	0
Ending balance (in shares) at Dec. 31, 2024	172,785,606	173,000,000
Ending balance at Dec. 31, 2024	$ 2,959	$ 2	$ 3,771	$ 242	$ 0	$ (1,056)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities
Net income	$ 479	$ 1,346	$ 1,343
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	555	561	578
Pension and postretirement benefit expense	34	41	64
Stock-based compensation expense	112	39	37
Gain on business divestitures	0	(56)	0
Deferred income taxes	(155)	(142)	(141)
Changes in assets and liabilities
Accounts receivable	43	(129)	(32)
Due from related parties	233	0	0
Inventories	(132)	23	(82)
Accounts payable	266	105	25
Due to related parties	(565)	0	0
All other operating activities	315	127	(113)
Net cash provided by operating activities	1,185	1,915	1,679
Cash Flows from Investing Activities
Purchases of property, plant and equipment	(380)	(290)	(251)
Proceeds from sale of business	0	60	0
Other — net	0	0	(2)
Net cash used in investing activities	(380)	(230)	(253)
Cash Flows from Financing Activities
Repayment of debt	(300)	0	0
Net transfers to 3M	(8,251)	(1,553)	(1,456)
Proceeds from long-term debt, net of issuance costs	8,303	0	0
Other — net	8	1	(4)
Net cash used in financing activities	(240)	(1,552)	(1,460)
Effect of exchange rate changes on cash and cash equivalents	3	0	4
Net increase (decrease) in cash and cash equivalents	568	133	(30)
Cash and cash equivalents at beginning of year	194	61	91
Cash and cash equivalents at end of year	762	194	61
Supplemental Cash Flow Information
Income taxes	244	0	0
Interest	$ 287	$ 0	$ 0

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Organization and Description of Business Solventum Corporation (“Solventum” or the “Company”) was a carve-out business of 3M Company (“3M”). On April 1, 2024 (the “Distribution Date”), 3M completed the previously announced spin-off of Solventum Corporation (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of 3M’s common stock as of the close of business on March 18, 2024 (the “Distribution”), which resulted in the issuance of 172,709,505 shares of common stock. As a result of the Distribution, the Company became an independent public company. Solventum’s common stock is listed under the symbol “SOLV” on the New York Stock Exchange (“NYSE”). Solventum is a leading global healthcare company with a broad portfolio of trusted solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. Solventum is organized into four operating business segments that are aligned with the end markets that the Company serves: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and present the historical results of operations, comprehensive income, and cash flows for the years ended December 31, 2024, 2023, and 2022, and financial position as of December 31, 2024 and 2023. Effective April 1, 2024, the Company’s financial statements are presented on a consolidated basis, as the Spin-Off was completed on such date. Prior to April 1, 2024, Solventum was a carve-out business of 3M. The Company's financial statements prior to April 1, 2024 were prepared on a combined basis and were derived from the consolidated financial statements and accounting records of 3M, including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by 3M. The financial statements included in this annual report are referred to as the “Consolidated Financial Statements” for all periods presented. Amounts reported within this annual report are rounded to the nearest million and the sum of the components may not equal the total amount reported due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding. All intercompany transactions and balances within Solventum have been eliminated. These consolidated financial statements include certain transactions with 3M, which are disclosed as related party transactions in Note 16 “Related Parties.” Foreign currency translation : Local currencies generally are considered the functional currencies outside the United States, and accordingly, the financial statements of these subsidiaries are remeasured as if their functional currency is that of their parent. Assets and liabilities for operations in local-currency environments are translated at month-end exchange rates of the period reported. Income and expense items are translated at average monthly currency exchange rates in effect during the period. Cumulative translation adjustments are recorded as a component of accumulated other comprehensive income (loss) in the consolidated balance sheets. Use of estimates : The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions are subject to inherent uncertainties which may result in actual amounts differing from those estimates. Cash and cash equivalents : Cash and cash equivalents included in the Company's consolidated balance sheets includes cash deposits, certificates of deposit, money market and other short-term funds with original maturities of three months or less. In periods prior to Spin-Off, the cash and cash equivalents reflected in the Company's consolidated balance sheet primarily represents cash managed by the Health Care Business as part of 3M's centralized cash program. Investments : All equity securities that do not result in consolidation and are not accounted for under the equity method are measured at fair value with changes therein reflected in other expense (income), net in the consolidated statements of income. Solventum utilizes the measurement alternative for equity investments that do not have readily determinable fair values and measures these investments at cost less impairment plus or minus observable price changes in orderly transactions. When conditions or occurrences change that are out of the ordinary, equity investments are analyzed for impairment. Solventum's equity investments are recognized within other assets in the consolidated balance sheets. Equipment held for use : Equipment held for use includes medical equipment in rental arrangements utilized primarily by hospitals and other medical clinics in conjunction with other medical consumables. Depreciation expense incurred on this equipment was $25 million, $32 million, and $28 million for the years ended December 31, 2024, 2023, and 2022, respectively. Equipment held for use is included in other assets on the consolidated balance sheets. Inventories : Inventories are stated at the lower of cost or net realizable value (NRV), which is defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Cost is generally determined on a first-in, first-out basis. Property, plant and equipment : Property, plant and equipment, including capitalized interest and internal direct engineering costs, are recorded at cost. Depreciation of property, plant and equipment generally is computed using the straight-line method based on the estimated useful lives of the assets. The estimated useful lives of buildings and improvements primarily range from ten twenty three five Goodwill : Goodwill is the excess of cost of an acquired entity over the amounts assigned to assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. Goodwill is tested for impairment annually in the fourth quarter of each year and is tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level, with all goodwill assigned to a reporting unit. Solventum reporting units correspond to a business segment as this represents the lowest level of discrete financial information below sales that is available and is regularly reviewed by segment management. The Company did not combine any of its reporting units for impairment testing. Any impairment loss is measured as the amount by which the carrying value of the reporting unit’s net assets exceeds its estimated fair value, not to exceed the carrying value of the reporting unit’s goodwill. The estimated fair value of a reporting unit is determined based on a market approach using comparable company information such as EBITDA (earnings before interest, taxes, depreciation and amortization) multiples or, in some cases, based on a discounted cash flow analysis. Intangible assets : Intangible asset types include customer-related, patents and other technology-based, tradenames and other intangible assets acquired from an independent party. Intangible assets with a definite life are amortized on a systematic and rational basis (generally straight line) that is representative of the asset’s use. The estimated useful lives vary by category, with customer-related between eleven six four Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable. An impairment loss is recognized when the carrying amount exceeds the estimated undiscounted cash flows from the asset’s or asset group’s ongoing use and eventual disposition. If an impairment is identified, the amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted cash flow analysis. Restructuring actions : We record liabilities for costs associated with exit activities in the period in which the liability is incurred. Employee termination costs are accrued when the restructuring is probable and estimable, which typically is when management approves the associated actions. Costs for one-time termination benefits in which the employee is required to render service in order to receive benefits at their termination dates are measured at the date such benefits were communicated to the applicable employees and recognized as expense over the future service period. Revenue recognition : The Company sells a wide range of products to a diversified base of customers around the world. The majority of Solventum’s customer arrangements contain a single performance obligation. The Company also enters into customer arrangements that involve multiple performance obligations (such as rental of equipment and related consumables), software with conterminous post-contract support, and software-as-a-service. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers . Revenue is recognized when control of goods has transferred to customers. For the majority of the Company’s customer arrangements, control transfers to customers at a point-in-time when goods have been delivered as that is generally when legal title, physical possession and the risks and rewards of ownership transfer to the customer. For certain arrangements, specifically software sold with coterminous post-contract support that is integral to maintaining the utility of the software license to the customer and software-as-a-service, control transfers over time as the customer simultaneously receives and consumes the benefits as the Company completes the performance obligation(s). Revenue is recognized at the transaction price which the Company expects to be entitled. The transaction price includes customer rebates, trade promotion funds, and cash discounts, which are accounted for as variable consideration. These sales incentives are recorded as a reduction to revenue at the time of the initial sale based on the most-likely estimate. The most-likely estimate considers historical experience, trend analysis, and projected market conditions in the various markets served. Because the Company serves numerous markets, the sales incentive programs offered vary across businesses, but the most common incentive relates to amounts paid or credited to customers for achieving defined volume levels or growth objectives. There are no material instances where variable consideration is constrained and not recorded at the initial time of sale. Sales, use, value-added, and other excise taxes are not recognized in revenue. The Company has elected to present revenue net of sales taxes and other similar taxes. Product returns are recorded as a reduction to revenue based on anticipated sales returns that occur in the normal course of business. The Company primarily has assurance-type warranties that do not result in separate performance obligations. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. For customers purchasing software from the Company, these performance obligations include providing software licenses with ongoing customer support, installation and training. For medical equipment arrangements, performance obligations include both furnishing a rental unit to a customer as well as delivery of consumables. The Company recognizes revenue from the rental of equipment in accordance with the guidance of ASC 842, Leases . The Company recognizes rental revenue based on the length of time a device is used by the patient/organization, (i) at the contracted rental rate for contracted customers, and (ii) generally, retail price for non-contracted customers. The leases are short-term in nature and are all classified as operating leases. The Company does not have material unfulfilled performance obligation balances for contracts with an original length greater than one year in any years presented. Additionally, the Company does not have material costs related to obtaining a contract with amortization periods greater than one year for any year presented. Accounts receivable and allowances : Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains allowances for bad debts, which are based on the best estimate of the amount of expected credit losses in existing accounts receivable. The Company determines the allowances based on historical write-off experience informed by industry and regional economic data, and current expectations of future credit losses. The Company reviews the allowances monthly. The allowances for bad debts as well as the provision for credit losses, write-off activity and recoveries for the periods presented are not material. Research and development : Research and development includes costs related to basic scientific research and the application of scientific advances in the development of new and improved products and their uses; technical support; internally developed patent costs; amortization of externally acquired patents and externally acquired in-process research and development. Research and development costs are expensed as incurred. Software costs : The Company capitalizes direct costs associated with the development of, and external software acquired for use as, internal-use software. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets. Amounts capitalized are amortized over a period of three For cloud computing arrangements that are considered service contracts, our capitalization of implementation costs is aligned with the internal use software requirements. However, on the Company's consolidated balance sheets, these implementation costs are recognized in other assets. On our consolidated statement of cash flows, these implementation costs are recognized as cash flows from operating activities. The implementation costs are recognized on a straight-line basis over the expected term of the related service contract. Income taxes : Prior to the Spin-Off, the Company was included in the consolidated U.S. federal, state, and foreign income tax returns of 3M, where applicable, through April 1, 2024. The Company's income tax provision for periods 2022, 2023 and the first quarter of 2024 was prepared using the separate return method. The calculation of income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations. As a result, transactions included in the consolidated financial statements of 3M may not be included in the Company's consolidated financial statements. Similarly, the tax treatment of certain items reflected in the Company's consolidated financial statements may not be reflected in the consolidated financial statements and tax returns of 3M. Therefore, items such as net operating losses, credit carryforwards, and valuation allowances may exist in the Company's standalone financial statements that may or may not exist in 3M’s consolidated financial statements. After the Spin-Off, the Company will file tax returns on its own behalf, and its income tax provision is prepared on a standalone basis. As a result, its deferred taxes and effective tax rate for 2024 may differ from those in the historical periods prior to Spin-Off. In jurisdictions where the Company has been included in income tax returns filed by 3M, income taxes currently payable will be deemed to have been remitted to 3M, in cash, in the period the liability arose and income taxes currently receivable are deemed to have been received from the Parent in the period that a refund could have been recognized. Adjustments to the recorded payable that derive from the Company's current year activity are recorded through current tax expenses and the ending adjusted payable/receivable is settled through “Net parent investment” on the consolidated balance sheets. Current obligations for tax in jurisdictions where the Company does not file a consolidated tax return with 3M, including certain foreign and certain U.S. state tax jurisdictions, are recorded as accrued liabilities within “Other current liabilities” on the consolidated balance sheets. The effects of tax adjustments and settlements with taxing authorities are presented in our consolidated financial statements in the period to which they relate. Uncertain tax positions that meet the more likely than not recognition threshold are measured to determine the amount of tax benefit to recognize in the consolidated financial statements. An uncertain tax position is measured at the largest amount of benefit that the Company believes has a greater than 50% likelihood of realization upon settlement. Tax benefits not meeting the measurement or realization criteria represent unrecognized tax benefits. The Company recognizes interest and penalties related to income tax matters as a component of “Provision for income taxes” in the consolidated statements of income. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their respective tax bases, as well as from net operating loss and tax credit carryforwards. The deferred income tax balances are stated at enacted tax rates expected to be in effect when those taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. We evaluate the recoverability of these future tax deductions and tax credits by evaluating all available positive and negative evidence, specifically assessing the adequacy of future expected taxable income from all sources, including reversal of existing taxable temporary differences, forecasted operating earnings, and available tax planning strategies. To the extent we consider it more likely than not that a deferred tax asset will not be recovered, a valuation allowance is established. Stock-based compensation : The Company recognizes compensation expense for its stock-based compensation awards, which include stock options, restricted stock units (RSUs), and performance share units (PSUs). In accordance with ASC 718, Compensation—Stock Compensation , the fair value of share-based compensation is determined at the grant date and the recognition of the related expense is recognized over the requisite service period. Prior to Spin-Off, certain employees participated in the stock-based compensation plans sponsored by 3M. The awards to these employees were reflected in “Net parent investment” within the consolidated statements of changes in equity at the time they were expensed. Comprehensive income : Total comprehensive income and the components of accumulated other comprehensive income (loss) are presented in the consolidated statements of comprehensive income and the consolidated statements of changes in equity. Accumulated other comprehensive income (loss) is composed of foreign currency translation effects, defined benefit pension adjustments and gains/losses from cash flow hedging activity. Fair value measurements: Solventum follows ASC 820, Fair Value Measurements , with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under the standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying value of the Company's accounts receivable, accounts payable, and accrued expenses approximate their fair value due to the short period of time to maturity or repayment. Leases : Solventum determines if an arrangement is a lease upon inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The right to control the use of an asset includes the right to obtain substantially all of the economic benefits of the underlying asset and the right to direct how and for what purpose the asset is used. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using Solventum’s incremental borrowing rate at lease commencement. Solventum determines the incremental borrowing rate for leases using a portfolio approach based primarily on the lease term and the economic environment of the applicable country or region. As a lessee, the Company leases distribution centers, office space, land, and equipment. Certain lease agreements include rental payments adjusted annually based on changes in an inflation index. The Company’s leases do not contain material residual value guarantees or material restrictive covenants. Lease expense is recognized on a straight-line basis over the lease term. Certain leases include one or more options to renew, with terms that can extend the lease term up to five years. The Company includes options to renew the lease as part of the right-of-use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options. For the measurement and classification of its lease agreements, the Company groups lease and non-lease components into a single lease component for all underlying asset classes. Variable lease payments primarily include payments for non-lease components, such as maintenance costs, payments for leased assets used beyond their noncancellable lease term as adjusted for contractual options to terminate or renew, additional payments related to a subsequent adjustment in an inflation index, and payments for non-components such as sales tax. Certain leases contain immaterial variable lease payments based on number of units produced. New Accounting Pronouncements The table below provides summaries of recently adopted financial accounting standards and recently issued financial accounting standards. Standard Relevant Description Effective Date for Solventum Impact of Adoption ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Issued in November 2023. Requires public entities to expand on segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Year-end December 31, 2024 The Company has assessed the impact of the updated standard and has included expanded disclosures within the business segment footnote. ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Issued in December 2023. Requires disaggregated information about a Company's effective tax rate reconciliation as well as information on income taxes paid. Year-end December 31, 2025 The Company is currently assessing the impact that the updated standard will have on financial statement disclosures. ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses Issued in November 2024. Requires additional disclosure of the nature of expenses included in the income statement. Year-end December 31, 2026 The Company is currently assessing the impact that the updated standard will have on financial statement disclosures.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Contract Balances Unearned revenue primarily relates to revenue that is recognized over time for one-year software license contracts. Approximately $550 million, $540 million, and $540 million of the December 31, 2023, 2022, and 2021 balance, respectively, was recognized as revenue during the years ended December 31, 2024, 2023, and 2022, respectively. Operating Lease Revenue Sales of software and rental Customer Concentration No customer accounted for more than 10% of the Company’s revenues for the years ended December 31, 2024, 2023, or 2022. Additionally, no customers accounted for more than 10% of accounts receivable as of December 31, 2024 and one customer accounted for approximately 10% of accounts receivable at December 31, 2023.
Revenue Recognition	Revenue Recognition Contract Balances Unearned revenue primarily relates to revenue that is recognized over time for one-year software license contracts. Approximately $550 million, $540 million, and $540 million of the December 31, 2023, 2022, and 2021 balance, respectively, was recognized as revenue during the years ended December 31, 2024, 2023, and 2022, respectively. Operating Lease Revenue Sales of software and rental Customer Concentration No customer accounted for more than 10% of the Company’s revenues for the years ended December 31, 2024, 2023, or 2022. Additionally, no customers accounted for more than 10% of accounts receivable as of December 31, 2024 and one customer accounted for approximately 10% of accounts receivable at December 31, 2023. Solventum's lease arrangements include both operating and finance leases. Amounts associated with finance leases were not material to the consolidated financial statements. Finance lease right-of-use assets are included in property, plant, and equipment - net, and finance lease liabilities are included in other current liabilities and other liabilities on the consolidated balance sheets. During the fourth quarter of 2024, Solventum entered into a finance lease arrangement through April 2046 for the future location of the Company's principal office in Eagan, Minnesota. The new location will include office, R&D and manufacturing space and the finance lease is expected to commence during the second quarter of 2026, at which time the Company will discontinue certain real estate license agreements with 3M. (Millions) 2024 2023 2022 Operating lease cost $ 75 $ 28 $ 32 Finance lease, variable lease costs, short-term lease cost and income related to sub-lease activity is immaterial for the Company. Supplemental balance sheet, lease term and discount rate information related to operating leases is as follows: December 31, (Millions unless noted) Location on face of Balance Sheet 2024 2023 Operating leases: Operating lease right of use assets Other assets $ 176 $ 98 Current operating lease liabilities Other current liabilities 87 29 Noncurrent operating lease liabilities Other liabilities 86 69 Total operating lease liabilities $ 173 $ 98 Weighted average remaining lease term (in years): 2.9 4.3 Weighted average discount rate: 4.2 % 2.9 % Supplemental cash flow information related to operating lease is as follows: (Millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: $ 76 $ 29 $ 31 Right of use assets obtained in exchange for operating lease liabilities: $ 148 $ 37 $ 14 There was no sale-leaseback activity for the periods presented. Maturities of operating leases as of December 31, 2024 are as follows: (Millions) 2025 $ 89 2026 44 2027 22 2028 10 2029 4 After 2029 7 Total expected lease payments 176 Less: Amounts representing interest (3) Present value of future minimum lease payments $ 173

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The goodwill balance by business segment is as follows: (Millions) MedSurg Dental Solutions Health Information Systems Purification and Filtration Total Balance as of December 31, 2022 $ 3,606 $ 452 $ 871 $ 1,505 $ 6,434 Divestiture — (4) — — (4) Translation impact 79 10 2 14 105 Balance as of December 31, 2023 3,685 458 873 1,519 6,535 Translation impact (88) (19) (2) (49) (158) Balance as of December 31, 2024 $ 3,597 $ 439 $ 871 $ 1,470 $ 6,377 The Company completed its annual goodwill impairment test in the fourth quarter of 2024 for all reporting units and determined that no impairment existed. There was no goodwill recorded from acquisitions during the years ended December 31, 2024 and 2023. In August 2023, 3M completed the sale of assets associated with its dental local anesthetic business (part of the Dental Solutions segment) to Pierrel S.p.A for approximately $60 million in cash. This transaction resulted in a net pre-tax gain of $56 million. In connection with this transaction, goodwill was reduced by approximately $4 million. Acquired Intangible Assets: The carrying amount and accumulated amortization of acquired finite-lived intangible assets, in addition to the balance of non-amortizable intangible assets are as follows: December 31, December 31, (Millions) 2024 2023 Customer related intangible assets $ 2,720 $ 2,734 Patents and other technology-based intangible assets 1,895 1,897 Tradenames and other amortizable intangible assets 729 705 Total gross carrying amount 5,344 5,336 Accumulated amortization — customer related (1,208) (1,081) Accumulated amortization — patents and other technology-based (1,224) (1,055) Accumulated amortization — tradenames and other (368) (323) Total accumulated amortization (2,800) (2,459) Total finite-lived intangible assets — net 2,544 2,877 Indefinite lived intangible assets — 25 Total intangible assets — net $ 2,544 $ 2,902 In June 2024, the Company made the decision to start phasing out the use of a tradename within its Dental Solutions business. This tradename, which was categorized as indefinite-lived as of December 31, 2023, has been reclassified to finite-lived and is being amortized over the expected phase-out period. Amortization expense was as follows: Year ended December 31, (Millions) 2024 2023 2022 Amortization expense $ 349 $ 365 $ 373 Expected amortization expense for acquired amortizable intangible assets recorded as of December 31, 2024 is as follows: (Millions) 2025 2026 2027 2028 2029 After 2029 Amortization expense $ 324 $ 319 $ 314 $ 309 $ 272 $ 1,006

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Other Current Liabilities	Other Current Liabilities Other current liabilities included in the consolidated balance sheets consist of the following: December 31, December 31, (Millions) 2024 2023 Other current liabilities Accrued compensation $ 281 $ 209 Accrued taxes 122 106 Accrued rebates 146 206 Accrued interest 114 — Other 378 156 Total other current liabilities $ 1,041 $ 677

Property, Plant, and Equipment

Property, Plant, and Equipment - Net	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant, and Equipment - Net	Property, Plant, and Equipment - Net Property, plant and equipment - net consisted of the following: December 31, December 31, (Millions) 2024 2023 Property, plant and equipment - at cost Buildings and leasehold improvements $ 956 $ 937 Machinery and equipment 2,150 2,081 Construction in progress 504 320 Gross property, plant and equipment 3,610 3,338 Accumulated depreciation (1,988) (1,881) Property, plant and equipment - net $ 1,622 $ 1,457 Depreciation expense consisted of the following: Year ended December 31, (Millions) 2024 2023 2022 Depreciation expense $ 181 $ 164 $ 177

Comprehensive Income Informatio

Comprehensive Income Information	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Comprehensive Income Information	Comprehensive Income Information Changes in Accumulated Other Comprehensive Income (Loss) by Component The table below presents the changes in accumulated other comprehensive income (loss) (“AOCI”), including the reclassifications out of AOCI by component: (Millions) Cumulative Translation Adjustment Defined Benefit Pension Cash Flow Hedging Total Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2021, net of tax $ (173) $ (27) $ — $ (200) Other comprehensive income (loss), before tax: Amounts before reclassifications (331) 45 — (286) Amounts reclassified out — 2 — 2 Total other comprehensive income (loss), before tax (331) 47 — (284) Tax effect — (13) — (13) Total other comprehensive income (loss), net of tax (331) 34 — (297) Transfers from 3M, net of tax — — — — Balance at December 31, 2022, net of tax: $ (504) $ 7 $ — $ (497) Other comprehensive income (loss), before tax: Amounts before reclassifications 157 (50) — 107 Amounts reclassified out — — — — Total other comprehensive income (loss), before tax 157 (50) — 107 Tax effect — 17 — 17 Total other comprehensive income (loss), net of tax 157 (33) — 124 Transfers from 3M, net of tax — 36 — 36 Balance at December 31, 2023, net of tax: $ (347) $ 10 $ — $ (337) Other comprehensive income (loss), before tax: Amounts before reclassifications (239) (44) 24 (259) Amounts reclassified out 38 39 2 79 Total other comprehensive income (loss), before tax (201) (5) 26 (180) Tax effect (2) — (6) (8) Total other comprehensive income (loss), net of tax (203) (5) 20 (188) Transfers from 3M, net of tax — (531) — (531) Balance at December 31, 2024, net of tax $ (550) $ (526) $ 20 $ (1,056) Additional details on the amounts reclassified from AOCI into consolidated income include: • Cumulative translation adjustment: amounts were reclassified into other expense (income), net and were related to charges associated with the substantial liquidation of foreign operations completed as part of our separation from 3M. • Defined benefit pension plans: amounts were reclassified into other expense (income), net (see Note 9). • Cash flow hedging: foreign currency forward contracts amounts were reclassified into cost of sales (see Note 10). • The tax effects, if applicable, associated with these reclassifications were reflected in provision for income taxes.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income (loss) before income taxes consisted of the following: (Millions) 2024 2023 2022 United States $ (47) $ 1,221 $ 1,276 International 652 446 416 Total $ 605 $ 1,667 $ 1,692 Provision (benefit) for income taxes consisted of the following: (Millions) 2024 2023 2022 Currently payable Federal $ 112 $ 148 $ 355 State 25 44 53 International 145 271 82 Deferred Federal (134) (8) (127) State (11) (9) (8) International (10) (125) (6) Total $ 127 $ 321 $ 349 Components of deferred tax assets and (liabilities) are comprised of the following: (Millions) 2024 2023 Deferred tax assets: Miscellaneous accruals $ 42 $ 52 Accrued compensation 159 102 Net operating/capital loss carryforward 55 95 Disallowed interest carryforwards 14 — Foreign tax credits 35 52 Advanced royalties — 26 Research and experimentation capitalization 129 213 Lease liabilities 32 16 Other deferred tax assets 20 37 Gross deferred tax assets 486 593 Valuation allowance (33) (56) Total deferred tax assets 453 537 Deferred tax liabilities: Property, plant, and equipment (78) (108) Intangible assets (278) (324) Right-of-use assets (33) (16) Total deferred tax liabilities (389) (448) Net deferred tax asset (liability) $ 64 $ 89 As displayed in the table above, as of December 31, 2024, the Company has provided $33 million of valuation allowance against certain of these deferred tax assets based on management’s determination that it is more-likely-than-not that the tax benefits related to these assets will not be realized. As of December 31, 2024 , the Company had tax-effected operating loss and capital loss carryf orwards of $55 million and tax credit carryforwards of $37 million for federal, state, and international jurisdictions, with all amounts before limitation impacts and valuation allowances. Federal and state tax attributes will expire after one to eighteen years and international tax attributes after one to an indefinite carryover period. A reconciliation of the U.S. federal statutory income tax rate to Solventum's worldwide effective income tax rate is provided below: 2024 2023 2022 U.S. Statutory income tax rate 21.0 % 21.0 % 21.0 % State income taxes - net of federal benefit 1.8 1.7 2.1 International income taxes - net (7.0) (1.3) (1.7) Global Intangible Low Taxed Income (GILTI) 4.2 0.8 0.7 Foreign Derived Intangible Income (FDII) (3.3) (2.2) (2.5) U.S. research and development credit (4.1) (1.2) (1.8) Reserves for tax contingencies (1.4) (4.1) 0.6 Tax impact of legal entity restructuring 4.7 2.3 — Changes in valuation allowance 2.6 1.4 0.7 Deferred rate change 0.9 0.1 (0.3) All other - net 1.5 0.8 1.8 Effective income tax rate 20.9 % 19.3 % 20.6 % The effective income tax rate for 2024 was 20.9%, compared to 19.3% in 2023, an increase of 1.6 percentage points. The primary factors that increased the tax rate were the tax impact of legal entity restructuring in connection with the Spin-Off, partially offset by the recognition of a previously unrecognized tax benefit due to the expiration of the statute of limitations. In 2021, the Organisation for Economic Co-operation and Development (“OECD”) announced Pillar Two Model Rules which call for the taxation of large multinational corporations at a global minimum tax rate of 15%. Many non-U.S. tax jurisdictions, including Ireland, have either recently enacted legislation to adopt certain components of the Pillar Two Model Rules beginning in fiscal year 2024 or announced their plans to enact legislation in future years. In 2024, the Company incurred insignificant tax impact in connection with Pillar Two. The Company recognizes the amount of income tax benefit that has a greater than 50% likelihood of being ultimately realized upon settlement. Changes in unrecognized tax benefits impacting the provision for income taxes of the Company have been reflected in the consolidated statements of income. Interest and penalties are also recognized in the provision for income taxes in the consolidated statements of income. For uncertain tax positions that the Company expects to be legally liable for, the unrecognized tax benefits and interest and penalties of $36 million and $40 million have been recorded to “Other liabilities” as of December 31, 2024 and 2023, respectively on the consolidated balance sheets. For uncertain tax positions where the Company is not legally and directly liable for, unrecognized tax benefits and interest and penalties are charged to “Net parent investment” on the consolidated balance sheets. A rollforward of unrecognized tax benefits (“UTB”) is as follows: (Millions) 2024 2023 2022 Gross UTB Balance at January 1 $ 205 $ 307 $ 308 Additions based on tax positions related to the current year 4 22 18 Additions for tax positions of prior years — 17 17 Additions related to recent acquisitions — — — Reductions for tax positions of prior years (64) (35) (19) Settlements — — — Reductions due to lapse of applicable statute of limitations (8) (74) (10) Reductions for amounts recorded to net parent investment — (32) (7) Gross UTB Balance at December 31 $ 137 $ 205 $ 307 The total amount of UTB, if recognized, would affect the effective tax rate by $141 million as of December 31, 2024. It is reasonably possible that the amount of unrecognized tax benefits could significantly change within the next 12 months. The Company has ongoing federal, state and international income tax audits in various jurisdictions and evaluates uncertain tax positions that may be challenged by local tax authorities and not fully sustained. These uncertain tax positions are reviewed on an ongoing basis and adjusted in light of facts and circumstances including progression of tax audits, developments in case law and closing statutes of limitation. At this time, the Company is not able to estimate the range by which these potential events could impact the Company’s unrecognized tax benefits within the next 12 months. There is audit activity in several U.S. Federal, state and foreign jurisdictions where the Company is subject to ongoing tax examinations and governmental assessments, which could be impacted by evolving political environments in those jurisdictions. As of December 31, 2024, no taxing authority proposed significant adjustments to the Company’s tax positions for which the Company is not adequately reserved. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in tax expense. The Company recognized in the consolidated statements of income on a gross basis approximately $1.0 million of benefit, $7.5 million of benefit and $3.9 million of expense in 2024, 2023 and 2022, respectively. The amount of interest and penalties recognized may be an expense or benefit due to new or remeasured unrecognized tax benefit accruals. At December 31, 2024 and 2023, accrued interest and penalties in the consolidated balance sheets on a gross basis were $5.3 million and $4.5 million, respectively. As of December 31, 2024, the Company provides for deferred taxes associated with foreign earnings in certain subsidiaries that are not considered permanently reinvested. The Company has not provided deferred taxes on approximately $2 billion of undistributed earnings from non-U.S. subsidiaries which are indefinitely reinvested in operations. It is not practical to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.

Long-Term Debt and Short-Term B

Long-Term Debt and Short-Term Borrowings	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt and Short-Term Borrowings	Long-Term Debt and Short-Term Borrowings Carrying value includes the impact of debt issuance costs. There were no long-term debt or short-term borrowings as of December 31, 2023. Long-term debt and short-term borrowings as of December 31, 2024 consisted of the following: (Millions) Currency/ Fixed vs. Floating Effective Interest Rate Final Maturity Date Carrying Value Description December 31, 2024 Eighteen USD Floating 6.13 % 2025 $ 200 Three USD Floating 6.13 2027 979 $1 billion 5.45 percent three USD Fixed 5.40 2027 995 $1.5 billion 5.40 percent five USD Fixed 5.39 2029 1,487 $1 billion 5.45 percent seven USD Fixed 5.45 2031 990 $1.65 billion 5.60 percent ten USD Fixed 5.63 2034 1,636 $1.25 billion 5.90 percent thirty USD Fixed 6.05 2054 1,231 $500 million 6.00 percent forty USD Fixed 6.17 2064 492 Other borrowings — Total long-term debt 8,010 Less: current portion of long-term debt 200 Long-term debt (excluding current portion) $ 7,810 Senior Notes On February 27, 2024, the Company issued six series of senior notes with a combined aggregate principal amount of $6.9 billion: $1 billion aggregate principal amount of 5.45% senior notes due 2027, $1.5 billion aggregate principal amount of 5.40% senior notes due 2029, $1 billion aggregate principal amount of 5.45% senior notes due 2031, $1.65 billion aggregate principal amount of 5.60% senior notes due 2034, $1.25 aggregate principal amount of 5.90% senior notes due 2054, and $0.5 billion aggregate principal amount of 6.00% senior notes due 2064 (collectively, the “Senior Notes”). Interest payments on the Senior Notes are due semi-annually until maturity, with the first round of payments being made from August to November of 2024 for each respective note. The Company recorded $62 million of debt issuance costs related to the Senior Notes. Debt issuance costs are presented as a reduction of debt in the consolidated balance sheets and are amortized as a component of interest expense over the term of the related debt using the effective interest method. In connection with the issuance of the senior notes, the Company entered into a registration rights agreement with the initial purchasers, pursuant to which the Company was obligated to use commercially reasonable efforts to file with the SEC and cause to become effective a registration statement with respect to an offer to exchange each series of Senior Notes for registered notes with terms that are substantially identical in all material respects to the notes of such series. On November 15, 2024, the Company filed with the SEC a registration statement on Form S-4 ("Registration Statement") which included an offer to exchange each series of unregistered notes ("Old Notes") for registered notes of like principal amount ("New Notes" and, together with the Old Notes, "Senior Notes"). The terms of the New Notes are identical in all material respects to the terms of the Old Notes of the corresponding series, except that the New Notes are registered under the Securities Act of 1933, will not contain restrictions on transfer or provisions relating to additional interest, will bear different CUSIP numbers from the Old Notes of the corresponding series, will not entitle their holders to registration rights, and will have different initial interest payment dates (semi-annual, with the first payment commencing February 2025). The SEC declared the Registration Statement effective on December 2, 2024. The Senior Notes were offered as part of the financing for the Spin-Off. In connection with the consummation of the Spin-Off, Solventum made direct and indirect cash payments to 3M as partial consideration for 3M’s transfer of its health care business to Solventum. All of the net proceeds from the offering of the notes were paid to 3M, other than amounts retained in order to achieve the $600 million retained cash target. The Senior Notes are governed by an indenture and supplemental indenture between the Company and a trustee (collectively, the “ Indenture ” ). The Indenture contains certain customary affirmative and negative covenants, including restrictions on the Company’s ability to consolidate, merge, convey, transfer or lease substantially all of its assets. In addition, the Indenture contains other customary terms, including certain events of default, upon the occurrence of which the Senior Notes may be declared immediately due and payable. Credit Facilities On February 16, 2024, the Company entered into credit agreements providing for: • a five year senior unsecured revolving credit facility in an aggregate committed amount of $2.0 billion expiring in 2029 (the “5-year Revolving Credit Facility”); and • an eighteen month senior unsecured term loan credit facility in an aggregate principal amount of $500 million and a three year senior unsecured term credit loan facility in an aggregate principal amount of $1.0 billion (together, the “ Term Loan Credit Facilities, ” and together with the 5-Year Revolving Credit Facility, the “Credit Facilities”). The Company intends to use the Credit Facilities for general corporate purposes. At December 31, 2024, there are no amounts outstanding under the 5-year Revolving Credit Facility. On March 7, 2024, the Company drew on the Term Loan Credit Facilities in the amount of $1.48 billion. These Term Loan Credit Facilities have a floating interest rate based on a Secured Overnight Financing Rate (“SOFR”) index. In August 2024, the Company paid $200 million of the aggregate principal amount outstanding under the eighteen month senior unsecured term loan credit facility. In December 2024, the Company paid an additional $100 million to the same eighteen month senior unsecured term loan credit facility, resulting in a remaining aggregate principal amount of $200 million outstanding at December 31, 2024. Commercial Paper On March 4, 2024, the Company entered into a commercial paper program that allows it to issue up to $2.0 billion aggregate principal amount of short-term notes to finance short-term liabilities. Any such issuance will mature within 364 days from date of issue. There was no commercial paper outstanding as of December 31, 2024. Future Maturities of Long-term Debt: Maturities of long-term debt in the table below reflect the impact of repayment such that total maturities equal the contractual value of long-term debt net of amounts repaid as of December 31, 2024. The maturities of long-term debt for the periods subsequent to December 31, 2024 are as follows (in millions): 2025 2026 2027 2028 2029 After 2029 Total $ 200 $ — $ 1,980 $ — $ 1,500 $ 4,400 $ 8,080 Financial Instruments Not Measured at Fair Value The fair values of cash equivalents, accounts receivable, and accounts payable approximated carrying values because of the short-term nature of these instruments. At December 31, 2024, the estimated fair value of the Company’s long-term debt obligations, comprised of both Senior Notes and Term Loan Credit Facilities with current portions excluded, was $7.8 billion compared to a carrying value of $7.8 billion. The Company did not have any outstanding debt obligations at December 31, 2023. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans Transfer of Pension and Postretirement Benefit Plans Historically, certain employees of Solventum participated in U.S. and non-U.S. retirement plans sponsored by 3M. In preparation for the Spin-Off, certain defined benefit plan obligations and assets relating to active Solventum employees and retirees were legally transferred from 3M Company to Solventum. Upon legal transfer, the related assets and liabilities were reflected in the consolidated balance sheets. These amounts are disclosed as “Transfers from 3M” in the following tables, and the net periodic benefit costs are included in the consolidated statements of income. Prior to the legal transfer, these plans were accounted for as multiemployer plans and a proportionate allocation of service costs associated with t he Solventum employees was reflected in the consolidated statements of income. Expenses associated with employees' participation in 3M Company sponsored pension plans were $5 million, $32 million, and $56 million for the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, all of the defined benefit plan obligations, all associated U.S. plan assets and the majority of the associated international plan assets related to Solventum employees have transferred from 3M to Solventum. Assets not yet delivered from 3M-sponsored pension plans due to regulatory purposes are already recognized within Solventum's plan assets and are expected to transfer during 2025. In total, Solventum has more than 25 defined-benefit pension plans in 14 countries. Pension benefits associated with these plans generally are based on each participant’s years of service, compensation, and age at retirement or termination. The primary U.S. defined-benefit pension plan was closed to new participants effective January 1, 2009. Prior to the Spin-Off, 3M committed to the future freeze of U.S. defined benefit pension benefits for non-union U.S. employees, effective December 31, 2028. As a successor plan to the 3M plan, the Solventum U.S. defined-benefit pension plan will also cease accruing benefits for non-union participants after December 31, 2028. In addition, Solventum offers certain postretirement health care and life insurance benefits for U.S. employees who reach a retirement age while employed by the Company and who were employed prior to January 1, 2016. The related plan obligations and associated plan assets are reflected in the following tables. Most international employees and retirees are covered by government health care programs. The cost of company-provided postretirement health care plans for international employees is not material. Assets of the U.S. qualified defined benefit pension plan and U.S. postretirement plans are held by independent trustees. There are no plan assets in the U.S. non-qualified plan due to its nature. In certain non-U.S. jurisdictions, trust funds and deposits with insurance companies are maintained to provide pension benefits to plan participants and their beneficiaries. The following tables include a reconciliation of the beginning and ending balances of the Company-sponsored benefit obligations and the fair value of plan assets, as well as a summary of the related amounts recognized in the consolidated balance sheets as of December 31 of the respective years: Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2024 2023 2024 2023 Change in benefit obligation Benefit obligation at beginning of year $ — $ — $ 519 $ 105 $ — $ — Service cost 20 — 18 5 3 — Interest cost 70 — 19 7 9 — Participant contributions — — 1 — — — Foreign exchange rate changes — — (36) 19 — — Actuarial (gain) loss (9) — (4) 70 (10) — Benefit payments (96) — (10) (8) (11) — Settlements, curtailments, special termination benefits and other (2) — 1 — (1) — Transfers from 3M 1,874 — 103 321 260 — Benefit obligation at end of year $ 1,857 $ — $ 611 $ 519 $ 250 $ — Change in plan assets Fair value of plan assets at beginning of year $ — $ — $ 367 $ 9 $ — $ — Actual return on plan assets 48 — 15 21 3 — Company contributions 3 — 16 11 1 — Participant contributions — — 1 — — — Foreign exchange rate changes — — (28) 16 — — Benefit payments (96) — (10) (8) (11) — Settlements, curtailments, special termination benefits and other (2) — — — (1) — Transfers from 3M 1,832 — 110 318 140 — Fair value of plan assets at end of year 1,785 — 471 367 132 — Funded status at end of year $ (72) $ — $ (140) $ (152) $ (118) $ — Amounts recognized in the Consolidated Balance Sheet as of December 31, (Millions) Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2024 2023 2024 2023 Other assets $ — $ — $ 18 $ 9 $ — $ — Accrued benefit cost Current liabilities (2) — (3) (1) (1) — Non-current liabilities (70) — (155) (160) (117) — Ending balance $ (72) $ — $ (140) $ (152) $ (118) $ — Amounts recognized in accumulated other comprehensive (income) loss as of December 31, (Millions) Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2024 2023 2024 2023 Net actuarial loss (gain) 658 — 4 (11) 47 — Prior service cost (credit) — — — — (15) — Ending balance $ 658 $ — $ 4 $ (11) $ 32 $ — The balance of amounts recognized for non-U.S. plans in accumulated other comprehensive income (loss) as of December 31, 2024 in the preceding table is presented based on the foreign currency exchange rates on that date. The pension accumulated benefit obligation represents the actuarial present value of benefits based on employee service and compensation as of the measurement date and does not include an assumption about future compensation levels. The following table summarizes the total accumulated benefit obligations, the accumulated benefit obligations and fair value of plan assets for defined benefit pension plans with accumulated benefit obligations in excess of plan assets, and the projected benefit obligation and fair value of plan assets for defined benefit pension plans with projected benefit obligation in excess of plan assets as of December 31, 2024: Qualified and Non-qualified Pension Plans United States International (Millions) 2024 2023 2024 2023 Accumulated benefit obligation $ 1,775 $ — $ 558 $ 460 Plans with accumulated benefit obligation in excess of plan assets Accumulated benefit obligation $ 22 $ — $ 405 $ 398 Fair value of plan assets — — 285 294 Plans with projected benefit obligation in excess of plan assets Projected benefit obligation $ 1,857 $ — $ 452 $ 476 Fair value of plan assets 1,785 — 294 316 Components of Net Periodic Cost and Other Amounts Recognized in Other Comprehensive Income: The service cost component of defined benefit net periodic benefit cost is recorded in cost of product, cost of software and rentals, selling, general and administrative expenses, and research and development expenses. As discussed in Note 6, the other components of net periodic benefit cost are reflected in other expense (income), net. Components of net periodic benefit cost and other supplemental information for the respective years ended December 31 are as follows: Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2022 2024 2023 2022 2024 2023 2022 Net periodic benefit cost (benefit) Operating expense Service cost $ 20 $ — $ — $ 18 $ 5 $ 6 $ 3 $ — $ — Non-operating expense Interest cost 70 — — 19 7 2 9 — — Expected return on plan assets (103) — — (20) (3) (1) (7) — — Amortization of prior service benefit (2) — — — — — (3) — — Amortization of net actuarial loss 40 — — — — — 3 — — Settlements, curtailments, special termination benefits and other 1 — — 1 — 2 — — — Total non-operating expense (benefit) 6 — — — 4 3 2 — — Total net periodic benefit cost (benefit) $ 26 $ — $ — $ 18 $ 9 $ 9 $ 5 $ — $ — Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Amortization of transition asset $ — $ — $ — $ — $ — $ (1) $ — $ — $ — Amortization of prior service benefit 2 — — — — — 3 — — Net actuarial (gain) loss 46 — — 1 52 (43) (6) — — Amortization of net actuarial loss (40) — — — 1 (1) (3) — — Foreign currency — — — — (2) (2) — — — Settlements, curtailments, special termination benefits and other (1) — — — (1) — — — — Total recognized in other comprehensive (income) loss 7 — — 1 50 (47) (6) — — Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 33 $ — $ — $ 19 $ 59 $ (38) $ (1) $ — $ — Weighted-Average Assumptions Used to Determine Benefit Obligations as of December 31: Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2022 2024 2023 2022 2024 2023 2022 Discount rate 5.64 % — % — % 3.54 % 3.30 % 4.59 % 5.60 % — % — % Compensation rate increase 3.77 % — % — % 2.88 % 2.90 % 3.22 % N/A N/A N/A Weighted-Average Assumptions Used to Determine Net Cost for Years Ended December 31: Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2022 2024 2023 2022 2024 2023 2022 Discount rate - service cost 5.31 % — % — % 3.43 % 4.88 % 2.18 % 5.30 % — % — % Discount rate - interest cost 5.20 — — 3.37 5.24 4.53 5.14 — — Expected return on assets 7.75 — — 4.69 4.61 6.53 7.85 — — Compensation rate increase 3.77 — — 2.89 2.89 3.00 N/A N/A N/A The U.S. postretirement health care benefit plan is a savings account benefit-based plan. The contributions provided by the Company to the health savings accounts increase 3% per year for employees who retired prior to January 1, 2016 and 1.5% for employees who retire on or after January 1, 2016. Therefore, the Company does not have material exposure to health care cost inflation related to its retirees. The Company determines the discount rate to measure plan liabilities as of the December 31 measurement date for the pension and postretirement benefit plans. The discount rate reflects the current rate at which the associated liabilities could be effectively settled. The Company sets its rate to reflect the yield of a portfolio of high quality, fixed-income debt instruments that would produce cash flows sufficient in timing and amount to settle projected future benefits. Actuarial gains in 2024 and losses in 2023 related to projected benefit obligations were primarily the result of changes in discount rates. The Company measures service cost and interest cost separately using the spot yield curve approach applied to each corresponding obligation. Service costs are determined based on duration-specific spot rates applied to the service cost cash flows. The interest cost calculation is determined by applying duration-specific spot rates to the year-by-year projected benefit payments. The spot yield curve approach does not affect the measurement of the total benefit obligations as the change in service and interest costs offset in the actuarial gains and losses recorded in other comprehensive income. In 2024, the Company’s assumption for the expected return on plan assets for the primary U.S. qualified pension plan was 7.75%. The expected return assumption is based on the strategic asset allocation of the plan, long term capital market return expectations and expected performance from active investment management. As of December 31, 2024, the Company’s 2025 expected long-term rate of return on U.S. plan assets is 7.25%, which is based on an asset allocation assumption of 13% global equities, 15% private equities, 57% fixed-income securities, and 15% absolute return investments independent of traditional performance benchmarks, along with positive returns from active investment management. The actual net rate of return on plan assets in 2024 was 3.2%. Return on assets assumptions for international pension plans are calculated on a plan-by-plan basis using plan asset allocations and expected long-term rate of return assumptions. For the years ended December 31, 2024, 2023, and 2022, the Company contributed $16 million, $11 million, and $4 million, respectively, to its international pension plans. In 2025, the Company expects to contrib ute $18 million to its international pension plans. The Company does not have required minimum cash contributions for its U.S. pension or postretirement plans for 2025. Future contributions will depend on market conditions, interest rates and other factors. Future Pension and Postretirement Benefit Payments The following table provides the estimated pension and postretirement benefit payments that are payable from the plans to participants: Qualified and Non-qualified Pension Benefits Postretirement Benefits (Millions) United States International 2025 Benefit payments $ 164 $ 23 $ 20 2026 Benefit payments 159 22 21 2027 Benefit payments 157 24 21 2028 Benefit payments 156 26 22 2029 Benefit payments 154 30 22 Next five years 737 160 104 Plan Asset Management Solventum's investment strategy for its pension and postretirement plans is to manage the funds on a going-concern basis. The primary goal of the trust funds is to meet the obligations as required. The secondary goal is to earn the highest rate of return possible, without jeopardizing its primary goal, and without subjecting the Company to an undue amount of contribution risk. Fund returns are used to help finance present and future obligations to the extent possible within actuarially determined funding limits and tax-determined asset limits, thus reducing the potential need for additional contributions from the Company. The investment strategy has used long duration cash bonds and derivative instruments to offset a significant portion of the interest rate sensitivity of pension liabilities. Normally, Solventum does not buy or sell any of its own securities as a direct investment for its pension and other postretirement benefit funds. However, due to external investment management of the funds, the plans may indirectly buy, sell or hold Solventum securities. The aggregate amount of Solventum securities are not considered to be material relative to the aggregate fund percentages. The discussion that follows references the fair value measurements of certain assets in terms of levels 1, 2 and 3. See Note 1 for descriptions of these levels. While the company believes the valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. U.S. Pension Plan and Postretirement Benefit Plan Assets The U.S. pension plan assets and U.S. postretirement plan assets are held in a master trust and are invested with the same investment objectives. In order to achieve the investment objectives, the investment policies include a target strategic asset allocation. The investment policies allow some tolerance around the target in recognition that market fluctuations and illiquidity of some investments may cause the allocation to a specific asset class to vary from the target allocation, potentially for long periods of time. Acceptable ranges have been designed to allow for deviation from strategic targets and to allow for the opportunity for tactical over- and under-weights. The portfolios will normally be rebalanced when the quarter-end asset allocation deviates from acceptable ranges. The allocation is reviewed regularly by the named fiduciary of the plans. The fair values of the assets held by the U.S. pension and postretirement benefit plans by asset class are as follows: Fair Value Measurements Using Inputs Considered as Investments Measured at Net Asset Value* Fair Value at December 31, Level 1 Level 2 Level 3 (Millions) 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 U.S. Pension Plans Cash and cash equivalents $ 333 $ — $ — $ — $ — $ — $ — $ — $ 333 $ — Equities 180 — — — — — — — 180 — Fixed income 35 — 701 — — — — — 736 — Absolute return — — — — — — 245 — 245 — Private equity — — — — — — 283 — 283 — Total $ 548 $ — $ 701 $ — $ — $ — $ 528 $ — $ 1,777 $ — Other items to reconcile to fair value of plan assets 8 — Fair value of plan assets $ 1,785 $ — Postretirement Benefit Plans Cash and cash equivalents $ 25 $ — $ — $ — $ — $ — $ — $ — $ 25 $ — Equities 13 — — — — — — — 13 — Fixed income 3 — 52 — — — — — 55 — Absolute return — — — — — — 18 — 18 — Private equity — — — — — — 21 — 21 — Total $ 41 $ — $ 52 $ — $ — $ — $ 39 $ — $ 132 $ — Other items to reconcile to fair value of plan assets — Fair value of plan assets $ 132 $ — * I n accordance with ASC 820-10, certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the fair value of the underlying assets owned by the fund, minus its liabilities then divided by the number of units outstanding and is determined by the investment manager or custodian of the fund. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the fair value of plan assets. Equities consist primarily of mandates in public equity securities managed to various public equity indices. Publicly traded equities are valued at the closing price reported in the active market in which the individual securities are traded. Fixed income investments include domestic government and corporate debt securities, as well as bond futures. The debt securities are valued at the closing price reported if traded on an active market or at yields currently available on comparable securities of issuers with similar credit ratings. Futures are valued at the closing price reported in active market in which the derivative is traded. Absolute return consists primarily of private partnership interests in hedge funds valued at NAV. The private equity portfolio consists of partnership interests valued at NAV. Other items to reconcile to fair value of plan assets include interest receivables. International Pension Plan Assets Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. The disclosure below of asset categories is presented in aggregate for the 13 defined benefit plans in 9 countries, which have plan assets; however, there is significant variation in asset allocation policy from country to country. Local regulations, local funding rules, and local financial and tax considerations are part of the funding and investment allocation process in each country. The Company provides standard funding and investment guidance to all international plans with more focused guidance to the larger plans. Each plan has its own strategic asset allocation. The asset allocations are reviewed periodically and rebalanced when necessary. The fair values of the assets held by the international pension plans by asset class are as follows: Fair Value Measurements Using Inputs Considered as Investments Measured at Net Asset Value* Fair Value at December 31, Level 1 Level 2 Level 3 (Millions) 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Cash and cash equivalents $ 3 $ 2 $ — $ — $ — $ — $ — $ — $ 3 $ 2 Equities 5 7 29 23 — — 19 24 53 54 Fixed income 6 6 217 188 — — 20 31 243 225 Absolute return — — — — 33 28 3 10 36 38 Private equity — — — — — — 48 47 48 47 Total $ 14 $ 15 $ 246 $ 211 $ 33 $ 28 $ 90 $ 112 $ 383 $ 366 Other items to reconcile to fair value of plan assets 88 1 Fair value of plan assets $ 471 $ 367 *In accordance with ASC 820-10, certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the fair value of the underlying assets owned by the fund, minus its liabilities, then divided by the number of units outstanding, and is determined by the investment manager or custodian of the fund. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the fair value of plan assets. Equities consist primarily of mandates in public equity securities managed to various public equity indices. Publicly traded equities are valued at the closing price reported in the active market in which the individual securities are traded. Fixed income investments include domestic and foreign government, and corporate debt securities. The debt securities are valued at the closing price reported if traded on an active market or at yields currently available on comparable securities of issuers with similar credit ratings. Absolute return consists of insurance contracts, which are valued using cash surrender values which is the amount the plan would receive if the contract were cashed out at year end. Private equity funds consist of partnership interests in a variety of funds which are valued at NAV as described above. Other items to reconcile to fair value of plan assets include a receivable from a 3M-sponsored pension plan that is expected to transfer to the Solventum-sponsored pension plan in 2025. The balances of and changes in the fair values of the international pension plans’ level 3 assets consist primarily of insurance contracts under the absolute return asset class which were transferred from 3M plans; these investments have few transactions. Defined Contribution Plans The Company also sponsors employee savings plans under Section 401(k) of the Internal Revenue Code. These plans are offered to substantially all regular U.S. employees. For eligible employees hired prior to January 1, 2009, employee 401(k) contributions of up to 5% of eligible compensation are matched in cash at rates of 45% or 60%, depending on the plan in which the employee participates. Employees hired on or after January 1, 2009, receive a cash match of 100% for employee 401(k) contributions of up to 5% of eligible compensation and receive an employer retirement income account cash contribution of 3% of the participant’s total eligible compensation. All contributions are invested in a number of investment funds pursuant to employees’ elections. Solventum subsidiaries in various international countries also participate in defined contribution plans. In 2024, expense related to the U.S. defined contribution plans was $93 million, and expense related to international defined contribution plans was $24 million. Prior to 2024, employees received employer contributions as part of 3M-sponsored plans.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Prior to April 1, 2024, Solventum indirectly participated in 3M’s centrally managed hedging program, which utilizes a number of tools to manage currency risk including natural hedges such as pricing, productivity, hard currency, hard currency-indexed billings, and localizing source of supply. 3M also used financial hedges to mitigate currency risk. After Spin-Off, the Company established its own hedging program. Cash Flow Hedges - For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period during which the hedged transaction affects earnings. Gains and losses on the derivative representing hedge components excluded from the assessment of effectiveness are recognized in current earnings. Cash Flow Hedging - Foreign Currency Forward Contracts: The Company enters into foreign exchange forward contracts to hedge against the effect of exchange rate fluctuations on cash flows denominated in foreign currencies. These transactions are designated as cash flow hedges. The settlement or extension of these derivatives will result in reclassifications (from accumulated other comprehensive income) to earnings in the period during which the hedged transactions affect earnings. Solventum may de-designate these cash flow hedge relationships in advance of the occurrence of the forecasted transaction. The portion of gains or losses on the derivative instrument previously included in accumulated other comprehensive income (loss) for de-designated hedges remains in accumulated other comprehensive income (loss) until the forecasted transaction occurs or becomes probable of not occurring. Changes in the value of derivative instruments after de-designation are recorded in earnings. The maximum length of time over which Solventum hedges its exposure to the variability in future cash flows of the forecasted transactions is 36 months. As of December 31, 2024, the Company had a balance of $20 million associated with the after-tax net unrealized gain associated with cash flow hedging instruments recorded in accumulated other comprehensive income. Of the total after-tax net unrealized balance as of December 31, 2024, Solventum expects to reclassify to earnings approximately $13 million after-tax net unrealized gain over the next 12 months based on exchange rates as of December 31, 2024. The amount of pretax gain (loss) recognized in other comprehensive income (loss) related to derivative instruments designated as cash flow hedges is provided in the following table. Pretax Gain (Loss) Recognized in Other Comprehensive Income (Loss) on Derivative Year ended December 31, (Millions) 2024 2023 2022 Foreign currency forward contracts $ 26 $ — $ — Net Investment Hedges - The Company enters into cross-currency swaps to hedge portions of the Company's investment in foreign subsidiaries and manage foreign exchange risk. For instruments that are designated and qualify as hedges of net investments in foreign operations and that meet the effectiveness requirements, the net gains and losses attributable to changes in spot exchange rates are recorded in cumulative translation within other comprehensive income. The remainder of the change in value of such instruments is recorded in earnings. Recognition in earnings of amounts previously recorded in cumulative translation is limited to circumstances such as complete or substantially complete liquidation of the net investment in the foreign operation. Solventum's use of cross-currency swaps designated as hedges of the Company's net investment in foreign subsidiaries can vary by time period in connection with the extent of the Company's desired foreign exchange risk coverage. At December 31, 2024, the total notional amount of cross-currency swaps designated as net investment hedges was approximately $380 million. The maturity of each of these derivative instruments designated as net investment hedges is March 1, 2029. The amount of gain (loss) excluded from effectiveness testing recognized in income relative to instruments designated in net investment hedge relationships is not material. The amount of pretax gain (loss) recognized in other comprehensive income (loss) related to derivative instruments designated as net investment hedges is provided in the following table. Pretax Gain (Loss) Recognized as Cumulative Translation within Other Comprehensive Income (Loss) Year ended December 31, (Millions) 2024 2023 2022 Cross-currency swaps $ 10 $ — $ — Derivatives Not Designated as Hedging Instruments - Derivatives not designated as hedging instruments include foreign currency contracts to offset, in part, the impacts of changes in value of various non-functional currency denominated items including certain intercompany financing balances. These derivative instruments are not designated in a hedging relationship; therefore, fair value gains and losses on these contracts are recorded in earnings. The Company does not hold or issue derivative financial instruments for trading purposes. Statement of Income Location and Impact of Cash Flow Derivative Instruments The impact to income related to both derivative instruments designated in cash flow hedging relationships and those not designated as hedging instruments for the year ended December 31, 2024 was not material. This impact was reflected within cost of sales on the consolidated statements of income. Location, Fair Value, and Gross Notional Amounts of Derivative Instruments The following tables summarize the fair value of Solventum’s derivative instruments and their location in the consolidated balance sheets. Notional amounts below are presented at period end foreign exchange rates. Gross Notional Amount Assets Liabilities (Millions) Location Fair Value Amount Location Fair Value Amount December 31, December 31, December 31, December 31, December 31, December 31, 2024 2023 2024 2023 2024 2023 Derivatives designated as hedging instruments Foreign currency forward contracts $ 355 $ — Other current assets $ 17 $ — Other current liabilities $ — $ — Foreign currency forward contracts 157 — Other assets 6 — Other liabilities — — Cross-currency swaps 380 $ — Other assets 10 $ — Other liabilities — $ — Total derivatives designated as hedging instruments $ 892 $ — $ 33 $ — $ — $ — Derivatives not designated as hedging instruments Foreign currency forward contracts $ 397 $ — Other current assets $ — $ — Other current liabilities $ — $ — Total derivatives not designated as hedging instruments $ 397 $ — $ — $ — $ — $ — Total derivative instruments $ 1,289 $ — $ 33 $ — $ — $ — The Company’s derivative assets and liabilities within the scope of ASC 815, Derivatives and Hedging , are required to be recorded at fair value. The Company’s derivatives that are recorded at fair value include foreign currency forward contracts and cross-currency swaps. Solventum has determined that these derivatives will be considered Level 2 fair value measurements. Solventum determines fair value using observable inputs including foreign currency exchange rates. Credit Risk and Offsetting of Assets and Liabilities of Derivative Instruments: The Company is exposed to credit loss in the event of nonperformance by counterparties in forward contracts. However, the Company’s risk is limited to the fair value of the instruments. The Company actively monitors its exposure to credit risk through the use of credit approvals and credit limits, and by selecting major international banks and financial institutions as counterparties. Solventum enters into master netting arrangements with counterparties, which may allow each counterparty to net settle amounts owed between a Solventum entity and the counterparty as a result of multiple, separate derivative transactions. The Company does not anticipate nonperformance by any of these counterparties. Solventum has elected to present the fair value of derivative assets and liabilities within the Company’s consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. Solventum determined that the impact of the amount of eligible offsetting derivative assets and liabilities was not material if it had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of netting arrangements with each of the counterparties. For each counterparty, if netted, the Company would offset the asset and liability balances of all derivatives at the end of the reporting period based on the Solventum entity that is a party to the transactions. Derivatives not subject to master netting agreements are not eligible for net presentation. For the periods presented, Solventum has not received cash collateral from derivative counterparties. Currency Effects: Solventum estimates that year-on-year foreign currency transaction effects, including hedging impacts, decreased pre-tax income by approximately $23 million in 2024, increased pre-tax income by approximately $9 million in 2023, and increased pre-tax income by approximately $27 million in 2022. These estimates include transaction gains and losses, including derivative instruments designed to reduce foreign currency exchange rate risks.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings Solventum is involved in numerous claims and lawsuits, principally in the United States, and regulatory proceedings worldwide. These claims, lawsuits and proceedings relate to matters including, but not limited to, product liability (involving products that the Company now or formerly manufactured and sold, including products made by the Health Care Business Group at 3M), intellectual property, commercial, antitrust, federal healthcare program related laws and regulations, such as the False Claims Act and anti-kickback laws in the United States and other jurisdictions. Unless otherwise stated, Solventum is vigorously defending all such litigation and proceedings. From time to time, Solventum also receives subpoenas, investigative demands or requests for information from various government agencies in the United States and foreign countries. Solventum generally responds in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such requests can also lead to the assertion of claims or the commencement of administrative, civil, or criminal legal proceedings against Solventum and others, as well as to settlements. The outcomes of legal proceedings and regulatory matters are often difficult to predict. Any determination that the Company’s operations or activities are not, or were not, in compliance with applicable laws or regulations could result in the imposition of fines, civil or criminal penalties, and equitable remedies, including disgorgement, suspension or debarment or injunctive relief. Process for Disclosure and Recording of Liabilities Related to Legal Proceedings Many lawsuits and claims involve highly complex issues relating to causation, scientific evidence, and alleged actual damages, all of which are otherwise subject to substantial uncertainties. Assessments of lawsuits and claims can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. The categories of legal proceedings in which the Company is involved may include multiple lawsuits and claims, may be spread across multiple jurisdictions and courts that may handle the lawsuits and claims differently, may involve numerous and different types of plaintiffs, raising claims and legal theories based on specific allegations that may not apply to other matters, and may seek substantial compensatory and, in some cases, punitive, damages. These and other factors contribute to the complexity of these lawsuits and claims and make it difficult for the Company to predict outcomes and make reasonable estimates of any resulting losses. The Company's ability to predict outcomes and make reasonable estimates of potential losses is further influenced by the fact that a resolution of one or more matters within a category of legal proceedings may impact the resolution of other matters in that category in terms of timing, amount of liability, or both. When making determinations about recording liabilities related to legal proceedings, the Company complies with the requirements of ASC 450, Contingencies , and related guidance, and records liabilities in those instances where it can reasonably estimate the amount of the loss and when the loss is probable. Where the reasonable estimate of the probable loss is a range, the Company records as an accrual in its financial statements the most likely estimate of the loss, or the low end of the range if there is no one best estimate. The Company either discloses the amount of a possible loss or range of loss in excess of established accruals if estimable, or states that such an estimate cannot be made. The Company discloses significant legal proceedings even where liability is not probable or the amount of the liability is not estimable, or both, if the Company believes there is at least a reasonable possibility that a loss may be incurred. Based on experience and developments, the Company reexamines its estimates of probable liabilities and associated expenses and receivables each period, and whether a loss previously determined to not be reasonably estimable and/or not probable is now able to be reasonably estimated or has become probable. Where appropriate, the Company makes additions to or adjustments of its reasonably estimated losses and/or accruals. As a result, the current accruals and/or estimates of loss and the estimates of the potential impact on the Company’s consolidated financial position, results of operations and cash flows for the legal proceedings and claims pending against the Company will likely change over time. During 2024 and 2023, the Company recognized $8 million and $9 million in legal charges, respectively. During the third quarter of 2024, the Company made a payment of $6 million related to a legal settlement, which reduced the accrued litigation balance. At December 31, 2024 and December 31, 2023, accrued litigation charges were $25 million and $23 million, respectively. Because litigation is subject to inherent uncertainties, and unfavorable rulings or developments could occur, the Company may ultimately incur charges substantially in excess of presently recorded liabilities, including with respect to matters for which no accruals are currently recorded because losses are not currently probable and reasonably estimable. Many of the matters described herein are at varying stages, seek an indeterminate amount of damages or seek damages in amounts that the Company believes are not indicative of the ultimate losses that may be incurred. It is not uncommon for claims to be resolved over many years. As a matter progresses, the Company may receive information, through plaintiff demands, through discovery, in the form of reports of purported experts, or in the context of settlement or mediation discussions that purport to quantify an amount of alleged damages, but with which the Company may not agree. Such information may or may not lead the Company to determine that it is able to make a reasonable estimate as to a probable loss or range of loss in connection with a matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in future changes to determinations of probable and reasonably estimable losses in other matters. Process for Disclosure and Recording of Insurance Receivables Related to Legal Proceedings The Company estimates insurance receivables based on an analysis of the terms of its numerous policies, including their exclusions, pertinent case law interpreting comparable policies, its experience with similar claims, and assessment of the nature of the claim and remaining coverage, and records an amount it has concluded is recognizable and expects to receive in light of the loss recovery and/or gain contingency models under ASC 450, ASC 610-30, and related guidance. For those insured legal proceedings for which the Company has recorded an accrued liability in its financial statements, the Company also records receivables for the amount of insurance that it concludes as recognizable from the Company’s insurance program. For those insured matters for which the Company has not recorded an accrued liability because the liability is not probable or the amount of the liability is not estimable, or both, but for which the Company has incurred an expense in defending itself, the Company records receivables for the amount of insurance that it concludes as recognizable for the expense incurred. Product Liability Litigation The following sections first describe the significant legal proceedings in which the Company is involved, and then describe the liabilities, if any, the Company has accrued relating to its significant legal proceedings. 3M is a named defendant in over 7,800 lawsuits in the United States and one Canadian putative class action with a single named plaintiff, alleging that they underwent various joint arthroplasty, cardiovascular, and other surgeries and later developed surgical site infections due to the use of the Bair Hugger patient warming system. Under the terms of the Separation and Distribution Agreement, dated as of March 31, 2024, by and between Solventum and 3M (the “Separation and Distribution Agreement”), Solventum has agreed to indemnify 3M for uninsured liabilities related to the Bair Hugger patient warming system, to manage the litigation, and pay for legal expenses. The plaintiffs seek damages and other relief based on theories of strict liability, negligence, breach of express and implied warranties, failure to warn, design and manufacturing defect, fraudulent and/or negligent misrepresentation/concealment, unjust enrichment, and violations of various state consumer fraud, deceptive or unlawful trade practices and/or false advertising acts. The U.S. Judicial Panel on Multidistrict Litigation ( “ JPML ” ) has consolidated all cases pending in federal courts to the U.S. District Court for the District of Minnesota to be managed in a multi-district litigation ( “ MDL ” ) proceeding. In July 2019, the court excluded several of the plaintiffs’ causation experts, and granted summary judgment for 3M in all cases pending at that time in the MDL; however, those decisions were subsequently reversed by the U.S. Court of Appeals for the Eighth Circuit. The parties are actively litigating several MDL bellwether and state court cases, with trials anticipated in 2025 and 2026. In addition to the federal MDL cases, there are six state court personal injury cases relating to the Bair Hugger patient warming systems. Additionally, a putative class action has been filed in Ramsey County, Minnesota, seeking economic damages for the use of the Bair Hugger system in knee and hip replacement surgeries involving medically obese people in Minnesota from May 2017 to the present. 3M had been named a defendant in 61 cases in Minnesota state court. In January 2018, the Minnesota state court excluded plaintiffs’ experts and granted 3M’s motion for summary judgment on general causation. The Minnesota Court of Appeals affirmed the state court orders in their entirety and the Minnesota Supreme Court denied plaintiffs’ petition for review and entered the final dismissal in 2019, effectively ending the Minnesota state court cases. In June 2016, 3M was served with a putative class action filed in the Ontario Superior Court of Justice for all Canadian residents who underwent various joint arthroplasty, cardiovascular, and other surgeries and later developed surgical site infections that the representative plaintiff claims were due to the use of the Bair Hugger patient warming system. The representative plaintiff seeks relief (including punitive damages) under Canadian law based on theories similar to those asserted in the MDL. For product liability litigation matters described in this section for which a liability has been recorded, the amount recorded is included in the disclosed amounts in the preceding “ Process for Disclosure and Recording of Liabilities Related to Legal Proceedings ” section and is not material to the Company’s results of operations or financial condition. In addition, the Company is not able to estimate a possible loss or range of possible loss in excess of the recorded liability at this time. Federal False Claims Act/Qui Tam Litigation In October 2019, 3M acquired Acelity, Inc. and its KCI subsidiaries, including Kinetic Concepts, Inc. and KCI USA, Inc. As previously disclosed in the SEC filings by the KCI entities, in 2009, Kinetic Concepts, Inc. received a subpoena from the U.S. Department of Health and Human Services Office of Inspector General. In 2011, following the completion of the government’s review and its decision declining to intervene in two qui tam actions described further below, the qui tam relator-plaintiffs’ pleadings were unsealed. The government inquiry followed two qui tam actions filed in 2008 by two former employees against Kinetic Concepts, Inc. and KCI USA, Inc. (collectively, the “ KCI Defendants ” ) under seal in the U.S. District Court for the Central District of California. One qui tam action (the Godecke case) was dismissed in January 2022. In the remaining action (the Hartpence case), the complaint contains allegations that the KCI Defendants violated the federal False Claims Act by submitting false or fraudulent claims to federal healthcare programs by billing for 3M V.A.C. Therapy in a manner that was not consistent with the Local Coverage Determinations issued by the Durable Medical Equipment Medicare Administrative Contractors and seeks monetary damages. In June 2019, the district court entered summary judgment in the KCI Defendants’ favor on all of the relator-plaintiff’s claims. The relator-plaintiff then filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. Oral argument in the Hartpence case was held in July 2020. The appellate court issued an opinion in August 2022 reversing the decision of the district court and remanding the case for further proceedings. The district court held a status conference in January 2023 during which no case deadlines were set; the litigation remains in a pre-trial stage. The KCI Defendants filed a renewed motion for summary judgment in March 2023. In July 2023, the parties filed a joint status report notifying the court of the parties’ agreement to mediate the matter in November 2023. As a result of a mediation held in November 2023, the relator-plaintiff and KCI reached an agreement in principle to settle the case and resolve all the remaining claims in this action, including the dismissal of the relator-plaintiff’s complaint with prejudice, subject to the agreement of the government and the parties’ negotiation and agreement of all remaining terms of the settlement. The KCI Defendants and relator-plaintiff have jointly requested that the court continue to hold in abeyance any hearing on the KCI Defendants’ pending Renewed Motion for Summary Judgment and any further proceedings in this case, to allow the parties to confer with counsel for the government and negotiate the remaining terms of the settlement agreement. The KCI Defendants and the relator-plaintiff submitted an updated status report to the court during January 2024 and updated status reports to the court periodically thereafter, most recently in January 2025. Under the terms of the Separation and Distribution Agreement, Solventum has agreed to indemnify 3M for liabilities related to this matter, to manage the litigation, and pay for related legal expenses. For the matters described in this section for which a liability has been recorded, the amount recorded is included in the disclosed amounts in the preceding “ Process for Disclosure and Recording of Liabilities Related to Legal Proceedings ” section and is not material to the Company’s consolidated results of operations or financial condition. The Company is not able to estimate a possible loss or range of possible loss in excess of the recorded liability at this time. Warranties/Guarantees The Company had approximately $40 million in bank guarantees, surety bonds, and other similar instruments issued and outstanding at December 31, 2024. These instruments are utilized in connection with normal business activities. Furthermore, the Company does not disclose information on its product warranties, as management considers the balance immaterial to its consolidated results of operations and financial condition.

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases Solventum's lease arrangements include both operating and finance leases. Amounts associated with finance leases were not material to the consolidated financial statements. Finance lease right-of-use assets are included in property, plant, and equipment - net, and finance lease liabilities are included in other current liabilities and other liabilities on the consolidated balance sheets. During the fourth quarter of 2024, Solventum entered into a finance lease arrangement through April 2046 for the future location of the Company's principal office in Eagan, Minnesota. The new location will include office, R&D and manufacturing space and the finance lease is expected to commence during the second quarter of 2026, at which time the Company will discontinue certain real estate license agreements with 3M. (Millions) 2024 2023 2022 Operating lease cost $ 75 $ 28 $ 32 Finance lease, variable lease costs, short-term lease cost and income related to sub-lease activity is immaterial for the Company. Supplemental balance sheet, lease term and discount rate information related to operating leases is as follows: December 31, (Millions unless noted) Location on face of Balance Sheet 2024 2023 Operating leases: Operating lease right of use assets Other assets $ 176 $ 98 Current operating lease liabilities Other current liabilities 87 29 Noncurrent operating lease liabilities Other liabilities 86 69 Total operating lease liabilities $ 173 $ 98 Weighted average remaining lease term (in years): 2.9 4.3 Weighted average discount rate: 4.2 % 2.9 % Supplemental cash flow information related to operating lease is as follows: (Millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: $ 76 $ 29 $ 31 Right of use assets obtained in exchange for operating lease liabilities: $ 148 $ 37 $ 14 There was no sale-leaseback activity for the periods presented. Maturities of operating leases as of December 31, 2024 are as follows: (Millions) 2025 $ 89 2026 44 2027 22 2028 10 2029 4 After 2029 7 Total expected lease payments 176 Less: Amounts representing interest (3) Present value of future minimum lease payments $ 173
Leases	Leases Solventum's lease arrangements include both operating and finance leases. Amounts associated with finance leases were not material to the consolidated financial statements. Finance lease right-of-use assets are included in property, plant, and equipment - net, and finance lease liabilities are included in other current liabilities and other liabilities on the consolidated balance sheets. During the fourth quarter of 2024, Solventum entered into a finance lease arrangement through April 2046 for the future location of the Company's principal office in Eagan, Minnesota. The new location will include office, R&D and manufacturing space and the finance lease is expected to commence during the second quarter of 2026, at which time the Company will discontinue certain real estate license agreements with 3M. (Millions) 2024 2023 2022 Operating lease cost $ 75 $ 28 $ 32 Finance lease, variable lease costs, short-term lease cost and income related to sub-lease activity is immaterial for the Company. Supplemental balance sheet, lease term and discount rate information related to operating leases is as follows: December 31, (Millions unless noted) Location on face of Balance Sheet 2024 2023 Operating leases: Operating lease right of use assets Other assets $ 176 $ 98 Current operating lease liabilities Other current liabilities 87 29 Noncurrent operating lease liabilities Other liabilities 86 69 Total operating lease liabilities $ 173 $ 98 Weighted average remaining lease term (in years): 2.9 4.3 Weighted average discount rate: 4.2 % 2.9 % Supplemental cash flow information related to operating lease is as follows: (Millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: $ 76 $ 29 $ 31 Right of use assets obtained in exchange for operating lease liabilities: $ 148 $ 37 $ 14 There was no sale-leaseback activity for the periods presented. Maturities of operating leases as of December 31, 2024 are as follows: (Millions) 2025 $ 89 2026 44 2027 22 2028 10 2029 4 After 2029 7 Total expected lease payments 176 Less: Amounts representing interest (3) Present value of future minimum lease payments $ 173
Leases	Revenue Recognition Contract Balances Unearned revenue primarily relates to revenue that is recognized over time for one-year software license contracts. Approximately $550 million, $540 million, and $540 million of the December 31, 2023, 2022, and 2021 balance, respectively, was recognized as revenue during the years ended December 31, 2024, 2023, and 2022, respectively. Operating Lease Revenue Sales of software and rental Customer Concentration No customer accounted for more than 10% of the Company’s revenues for the years ended December 31, 2024, 2023, or 2022. Additionally, no customers accounted for more than 10% of accounts receivable as of December 31, 2024 and one customer accounted for approximately 10% of accounts receivable at December 31, 2023. Solventum's lease arrangements include both operating and finance leases. Amounts associated with finance leases were not material to the consolidated financial statements. Finance lease right-of-use assets are included in property, plant, and equipment - net, and finance lease liabilities are included in other current liabilities and other liabilities on the consolidated balance sheets. During the fourth quarter of 2024, Solventum entered into a finance lease arrangement through April 2046 for the future location of the Company's principal office in Eagan, Minnesota. The new location will include office, R&D and manufacturing space and the finance lease is expected to commence during the second quarter of 2026, at which time the Company will discontinue certain real estate license agreements with 3M. (Millions) 2024 2023 2022 Operating lease cost $ 75 $ 28 $ 32 Finance lease, variable lease costs, short-term lease cost and income related to sub-lease activity is immaterial for the Company. Supplemental balance sheet, lease term and discount rate information related to operating leases is as follows: December 31, (Millions unless noted) Location on face of Balance Sheet 2024 2023 Operating leases: Operating lease right of use assets Other assets $ 176 $ 98 Current operating lease liabilities Other current liabilities 87 29 Noncurrent operating lease liabilities Other liabilities 86 69 Total operating lease liabilities $ 173 $ 98 Weighted average remaining lease term (in years): 2.9 4.3 Weighted average discount rate: 4.2 % 2.9 % Supplemental cash flow information related to operating lease is as follows: (Millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: $ 76 $ 29 $ 31 Right of use assets obtained in exchange for operating lease liabilities: $ 148 $ 37 $ 14 There was no sale-leaseback activity for the periods presented. Maturities of operating leases as of December 31, 2024 are as follows: (Millions) 2025 $ 89 2026 44 2027 22 2028 10 2029 4 After 2029 7 Total expected lease payments 176 Less: Amounts representing interest (3) Present value of future minimum lease payments $ 173

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the fourth quarter of 2024, the Company announced its Solventum Way restructuring program, which is a reorganization designed to establish a more flexible and decentralized structure, create headroom to invest for growth and an operating model that enhances margins over time. In 2024, the Company recorded a pre-tax charge of $62 million associated with this program. Solventum expects to commit to further actions under this program and also expects that substantially all actions will be complete by the end of 2025. The related restructuring charges for periods presented were recorded in the consolidated statement of income as follows: (Millions) 2024 Cost of product $ 17 Cost of software and rentals 2 Selling, general and administrative expenses 36 Research and development expenses 7 Total operating income impact $ 62 Restructuring actions, including cash and non-cash impacts, are as follows: (Millions) Employee Termination Benefits Asset-Related and Other Total Expense incurred in 2024 $ 46 $ 16 $ 62 Non-cash changes — (8) (8) Cash payments (1) — (1) Accrued liabilities as of December 31, 2024 $ 45 $ 8 $ 53 Asset-related and other primarily includes charges associate with asset write-offs and other contractual third party termination costs. All program charges were recognized within Corporate and are not included within business segment results.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Prior to the completion of the Spin-Off, the Company had no common shares issued and outstanding. On April 1, 2024, there were 172,709,505 shares of Solventum common stock issued and outstanding as part of the Distribution. This share amount is utilized for the calculation of basic and diluted earnings per share ("EPS") for all periods presented prior to the Spin-Off. For the years ended December 31, 2023 and 2022, these shares are treated as issued and outstanding for purposes of calculating historical earnings per share. Subsequent to Spin-Off, the dilutive effect of outstanding stock options, restricted stock units ("RSUs") and performance share units ("PSUs") is reflected in the calculation of EPS using the treasury stock method. As of December 31, 2024, dilutive earnings per share excludes 4 million shares issuable under stock-based compensation plans because the effect would have been antidilutive. For periods prior to the Spin-Off, it is assumed that there are no dilutive equity instruments as there were no equity awards of Solventum outstanding prior to the Spin-Off. The computations for basic and diluted EPS are as follows: Year ended December 31, (Amounts in millions, except per share amounts) 2024 2023 2022 Numerator: Net income $ 479 $ 1,346 $ 1,343 Denominator: Weighted average common shares outstanding – basic 173.2 172.7 172.7 Dilution associated with stock-based compensation plans 0.5 — — Weighted average common shares outstanding – diluted 173.7 172.7 172.7 Basic earnings per share $ 2.77 $ 7.79 $ 7.78 Diluted earnings per share $ 2.76 $ 7.79 $ 7.78

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Prior to the Spin-Off, certain eligible employees were awarded incentive stock options, non-qualified stock options, stock appreciation rights, RSUs, and PSUs under 3M's Amended and Restated 2016 Long-Term Incentive Plan (“3M Company Plan”). Stock-based compensation granted pursuant to the 3M Company Plan was based on 3M’s common stock. In March 2024, 3M's Board of Directors approved the 2024 Long-Term Incentive Plan (“Solventum 2024 Plan”) providing for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, RSUs, PSUs, and other stock or cash-based awards to eligible employees and non-employee directors. Stock-based compensation granted pursuant to the Solventum 2024 Plan is based on Solventum's stock. The maximum shares that can be issued under the Solventum 2024 Plan is 13,000,000 shares. In connection with the Spin-Off, all awards granted under the 3M Company Plan for Solventum employees were converted into equivalent awards under the Solventum 2024 Plan in April 2024. The stock award modification at Spin-Off resulted in incremental compensation cost of $22 million, of which $20 million was recognized during the year ended December 31, 2024, and $2 million will be recognized over the remaining requisite service period of the unvested awards as of December 31, 2024. Solventum grants annual stock-based compensation awards to certain employees and non-employee directors. In 2024, the annual grant occurred in May after the Spin-Off and included grants of RSUs and PSUs. In addition to the annual grant, the Company awarded one-time founders' RSUs and inducement PSUs to certain employees and non-employee directors in connection with the Spin-Off. The Company makes other minor grants of RSUs during the year. Compensation expense related to stock-based awards is recorded over the requisite service period of the awards. The Company estimates forfeitures based on experience and adjusts expense to reflect actual forfeitures. The annual grant contains a retirement provision whereby employees who have reached age 55 and completed ten years of service with the Company will continue to vest in their award after they retire. For these awards, expense is recognized over the required service period, from the grant date through the employees' retirement eligibility date. The compensation cost of awards to grant recipients who meet these conditions on the grant date is recognized on the grant date. Stock-Based Compensation Expense Amounts recognized in the consolidated financial statements related to stock-based compensation awards, including stock options, RSUs, and PSUs, are provided in the following table. Total stock-based compensation expense recognized in cost of product and cost of software and rentals has been combined in the table below as cost of sales. Capitalized stock-based compensation amounts were not material. Year ended December 31, (Millions) 2024 2023 2022 Cost of sales $ 14 $ 8 $ 8 Selling, general and administrative expenses 82 23 20 Research and development expenses 16 8 9 Stock-based compensation expenses 112 39 37 Income tax benefits (18) (9) (9) Stock-based compensation expenses, net of tax $ 94 $ 30 $ 28 Stock Options The following table summarizes stock option activity: (Options in thousands) Number of Options Weighted Average Exercise Price Weighted Average Aggregate Outstanding as of April 1, 2024 (1) 4,073 $ 106.45 Granted — — Exercised — — Forfeited (35) 86.46 Expired (47) 106.52 Outstanding as of December 31, 2024 3,991 106.63 55 $ — Exercisable as of December 31, 2024 3,571 108.56 51 — Expected to vest 419 $ 90.30 90 $ — (1) Solventum common stock began trading on the New York Stock Exchange (NYSE) on April 1, 2024. The shares outstanding as of April 1 2024 pertain to 3M Company equity-based awards issued by 3M in prior periods to employees and non-employee directors of the Company that were converted to Solventum equity-based awards as part of the Spin-Off. Stock options outstanding and exercisable in the table above relate to the awards previously granted under 3M Company. The outstanding stock options vest over a period of three years from the grant date and expire ten years from the grant date. There have been no stock options granted under the Solventum 2024 Plan. As of December 31, 2024, there was $1.5 million of compensation expense that has yet to be recognized related to non-vested stock options. This expense is expected to be recognized over the remaining weighted-average service period of 10 months. Restricted Stock Units RSUs contain service-only conditions for vesting . The fair value of RSUs is based upon the closing stock price on the grant date, and the awards generally vest over periods ranging from one (Units in thousands) Number of Shares Weighted Average Grant Date Fair Value Nonvested as of April 1, 2024 (1) 1,304 $ 76.93 Granted 2,305 62.77 Vested (136) 67.12 Forfeited (136) 68.54 Nonvested as of December 31, 2024 3,337 $ 67.89 (1) Solventum common stock began trading on the New York Stock Exchange (NYSE) on April 1, 2024. The shares outstanding as of April 1, 2024 pertain to 3M Company equity-based awards issued by 3M in prior periods to employees and non-employee directors of the Company that were converted to Solventum equity-based awards as part of the Spin-Off. As of December 31, 2024, there was $107 million of compensation expense that has yet to be recognized related to non-vested RSUs. This expense is expected to be recognized over the remaining weighted-average service period of 22 months. The following table summarizes additional information relative to RSUs for the respective years. There were no Solventum equity-based awards prior to the Spin-Off: (in millions, except per-share amounts) 2024 2023 2022 Weighted average grant date fair value of restricted stock units (per unit) that were granted $ 62.77 $ — $ — Total fair value of restricted stock units that vested $ 9 $ — $ — Performance Share Units As part of the annual grant, the Company grants PSUs to members of its executive management. PSUs contain both service conditions and performance conditions for vesting. The 2024 performance criteria include cumulative three-year targets for constant currency revenue and adjusted earnings per share. The number of shares of common stock that could actually be distributed at the end of the three-year performance period may be anywhere from 0% to 200%, depending on the performance of the Company compared to the cumulative 3-year performance targets. Because the cumulative 3-year performance targets have not been set as of December 31, 2024, the grant date has not been established. The Company began accruing the compensation cost related to these awards on the service inception date and remeasures the awards at fair value each reporting period, based on the Company's closing stock price as of the reporting date. As of December 31, 2024, there was $37 million of compensation expense that has yet to be recognized related to PSUs. This expense is expected to be recognized over the remaining weighted-average service period o f 24 months .

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
Related Parties	Related Parties Related Party Transactions Prior to Spin-Off Prior to the Spin-Off, the Company participated in centralized 3M treasury programs. This arrangement was not reflective of the manner in which the Company would have financed its operations had it been a standalone business separate from 3M during the periods presented prior to April 1, 2024. All adjustments relating to certain transactions among the Company and 3M, which include the transfer of the balance of cash to and from 3M, transfer of the balance of cash held in centralized cash management arrangements to and from 3M, and pushdown of all costs of doing business that were paid on behalf of the Company by 3M, are excluded from the asset and liability balances in the consolidated balance sheets and have instead been reported within Net parent investment as a component of equity . Corporate Allocations The consolidated statements of income for periods prior to April 1, 2024 include general corporate expenses of 3M for services provided by 3M for certain corporate and shared service functions that were provided on a centralized basis, including the use of shared assets. Expenses had been included on a direct usage basis where costs were specifically identifiable to Solventum or allocated based on the Company’s pro rata proportion of 3M's revenue. Management believes that the expense allocations were determined on a basis that was a reasonable reflection of the utilization of services provided for or the benefit received by the Company during each of the periods presented prior to April 1, 2024. The amounts that would have been incurred on a standalone basis could materially differ from the amounts allocated. Management does not believe, however, that it is practicable to estimate what these expenses would have been had the Company operated as an independent entity, including any expenses associated with obtaining any of these services from unaffiliated entities. There was no expense allocation activity after April 1, 2024. 3M expense allocations were recorded in the consolidated statements of income within the following captions: Twelve months ended December 31, (Millions) 2024 2023 2022 Costs of product $ 15 $ 89 $ 74 Costs of software and rentals — — — Selling, general and administrative expenses 177 678 617 Research and development expenses 28 86 87 Total $ 220 $ 853 $ 778 Related Party Transactions After Spin-Off Separation and Distribution Agreement and Other Related Party Transactions with 3M In connection with the Spin-Off on April 1, 2024, the Company entered into or adopted several agreements that provide a framework for Solventum's relationship with 3M after the separation and distribution. These include, but are not limited to, the following: • Separation and Distribution Agreement - The separation and distribution agreement contains key provisions related to the separation of Solventum from 3M, including the transfer of assets and assumptions of liabilities. In connection with this agreement, certain assets and liabilities included in the Company's consolidated balance sheet as of March 31, 2024 were retained by 3M and certain assets and liabilities not included in the Company’s consolidated balance sheet as of March 31, 2024 were transferred to Solventum as of the date of separation. Separation related adjustments resulted in a decrease to net assets and total equity of $1.1 billion and are reflected in the “Net transfers to 3M” line item of the consolidated statements of changes in equity. The impact on net assets primarily represent liabilities payable to 3M for services received prior to Spin-Off as well as cash and accounts receivable retained by 3M. • Transition Agreements - Transition services agreements include services that 3M will provide to Solventum and its affiliates, and Solventum and its affiliates will provide to 3M and its affiliates, on an interim, transitional basis. 1) Transition services agreement. Includes various services, including, but not limited to, information technology support and access, logistics services, certain finance support functions, compliance reporting, human resources and toxicology laboratory support services. The transition services agreement has an overall term of two years, subject to a potential one-year extension as determined by the parties. 2) Transition distribution services agreement. Provides that 3M and its affiliates will retain inventories of and purchase certain Solventum products from Solventum and its subsidiaries and distribute those products to Solventum’s customers. The transition distribution services agreement has an overall term of two years, with shorter terms for individual countries, subject to a potential one-year extension as determined by the parties. 3) Transition contract manufacturing agreement. Solventum and 3M will manufacture certain products of the other party at specified manufacturing sites and will supply such products to the other party, in each case on a transitional basis to allow for the orderly exit of production at the supplier site and relocation. The transition contract manufacturing agreement has an overall term of three years, with the terms of individual services ranging from eighteen For the year ended December 31, 2024, Solventum recognized cost of product and operating expense (which is comprised of selling, general and administrative and research and development expenses) of $369 million related to services received under the above transition agreements between the Company and 3M and its affiliates. • Tax Matters Agreement - The agreement governs the parties’ respective rights, responsibilities and obligations with respect to taxes (including responsibility for taxes, entitlement to refunds, allocation of tax attributes, preparation of tax returns, control of tax contests and other tax matters). In addition, the tax matters agreement imposes certain restrictions on Solventum and its subsidiaries (including restrictions on share issuances, business combinations, sales of assets and similar transactions) that are designed to preserve the tax-free status of the distribution and certain related transactions. • Employee Matters Agreement - The agreement allocates liabilities and responsibilities relating to employment matters, employee compensation and benefits plans and programs, and other related matters. The employee matters agreement provides that, unless otherwise specified, each party will be responsible for liabilities associated with current and former employees of such party and its subsidiaries. For the U.S. qualified and non-qualified defined benefit pension plans, Solventum established plans that mirror the corresponding 3M plans and assumed all obligations under 3M’s plans for the accrued benefits of current and former Solventum employees. The employee matters agreement also governs the terms of equity-based awards granted by 3M prior to separation. • Real Estate License Agreements - Solventum or one of its affiliates, as licensee, has entered into certain real estate license agreements with 3M or one of its affiliates, as licensor, pursuant to which Solventum will be able to continue to use certain premises owned or leased by 3M for a limited period of time following the distribution date. Pursuant to the real estate license agreements, 3M will provide customary building services to the licensee consistent with the property’s use prior to the separation, including, without limitation, basic utilities, janitorial and trash removal services, maintenance services and employee amenities. The terms of the real estate license agreements are generally two years or less. • Master Supply Agreements - 3M and Solventum entered into master supply agreements in connection with the separation under which each agrees to supply the other with certain products. The term of the master supply agreements will initially be three years, which will extend automatically, with the length of the term extension subject to the parties' ability to identify a third-party supplier, and the ability for such third-party supplier to provide validated production samples. The Company recognized revenue and cost of sales associated with products sold to 3M of $50 million and $37 million, respectively, for the year ended December 31, 2024. Cost of sales related to purchases from 3M under the master supply agreements was $128 million for the year ended December 31, 2024. Related Party Transactions The Company had the following transactions with 3M and its affiliates, primarily in connection with the Transition Services Agreement, Transition Distribution Services Agreement, Transition Contract Manufacturing Agreements and Master Supply Agreements, reported in the Company’s consolidated financial statements: Year ended December 31, (Amounts in millions) 2024 2023 Net sales of product $ 50 $ — Cost of product 357 — Selling, general and administrative expenses 202 — Research and development expenses 8 — Current amounts due from and due to 3M under various agreements described above are recognized within the “Due from related parties” and “Due to related parties,” as applicable, in the consolidated financial statements. Non-current amounts due to 3M in connection with the transition distribution services agreement were approximately $170 million at December 31, 2024 and were recognized in “Other liabilities” in the consolidated balance sheet. Net Parent Investment Net transfers to 3M are included within Net parent investment in the consolidated statements of changes in equity and within financing activities in the consolidated statements of cash flows and represent the net effect of transactions between the Company and 3M. The reconciliation of net transfers to 3M between the consolidated changes in equity and the consolidated statements of cash flows are as follows: Year ended December 31, (Millions) 2024 2023 2022 Net transfers to 3M on the consolidated changes in equity $ (8,571) $ (1,582) $ (1,363) Stock compensation expense (4) (39) (37) Multiemployer pension expense (5) (32) (56) Net balances transferred from 3M 329 100 — Net transfers to 3M on the consolidated statements of cash flows $ (8,251) $ (1,553) $ (1,456)

Business Segments

Business Segments	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Business Segments	Business Segments Operating segments include components of an enterprise where separate financial information is available that is evaluated regularly by the Company’s Chief Operating Decision Maker ( “ CODM ” ) for the purpose of assessing performance and allocating resources. The Company’s CODM is its Chief Executive Officer. The primary profitability measurement used by the CODM to review segment operating results is segment operating income. The CODM uses segment operating income to allocate resources during the annual strategic planning process and then holds the segments accountable to the resourcing decisions during the annual budgeting process. The CODM does not use asset information by segment to evaluate operating segments as they do not receive discrete asset information by segment. The Company’s operating activities are managed through four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. There have been no changes to the composition of the segments or to financial information reported within each of the business segments. These segments have been identified based on the nature of the products sold and how the Company manages its operations. Transactions among reportable segments are recorded at cost. No operating segments have been aggregated to form reportable segments. Corporate and Unallocated primarily includes amortization of acquired intangible assets, restructuring and related charges, benefits or costs related to capitalized manufacturing variances, and Spin-Off and separation related costs. Spin-Off and separation related costs include any costs incurred as part of our separation from 3M and costs to set up operations as a standalone company, including system implementations, manufacturing relocation, legal entity separation, certain equity awards granted as part of the Spin-Off, profit mark-ups on transition service arrangements with 3M and other one-time costs. Corporate and Unallocated also includes sales and cost of sales related to our supply agreements with 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses. Because Corporate and Unallocated includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis. Business segment operating income is reconciled to total operating income and pre-tax income below. Consistent accounting policies have been applied on a consolidated basis as well as by all segments for all reporting periods. A description of our reportable segments is as follows: Business Segment Offerings: Business Segment Representative revenue-generating activities, products or services MedSurg • P rovider of a broad range of innovative, advanced wound care and surgical solutions that are intended to accelerate healing, prevent complications and lower the total cost of care globally. Dental Solutions • Provider of a comprehensive suite of dental and orthodontic products that span the life of the tooth, which are intended to address clinical needs in prevention, restoration, replacement, and malocclusion correction. Health Information Systems • P rovider of software solutions and services that are designed to create more time for clinicians to care for patients, improve accuracy in healthcare reimbursement, and support the shift to value-based care. Purification and Filtration • Provider of filters and membranes for use in the manufacturing of biopharmaceutical and medical technologies, microelectronics and food and beverage products, as well as filtration for cleaner drinking water. Business Segment Information Year ended December 31, Net Sales (Millions) 2024 2023 2022 MedSurg $ 4,637 $ 4,632 $ 4,585 Dental Solutions 1,295 1,329 1,327 Health Information Systems 1,306 1,285 1,227 Purification and Filtration 956 951 991 Corporate and Unallocated 59 — — Total Company $ 8,254 $ 8,197 $ 8,130 Year ended December 31, Cost of Sales (Millions) 2024 2023 2022 MedSurg $ 2,151 $ 2,087 $ 2,085 Dental Solutions 425 455 471 Health Information Systems 361 358 361 Purification and Filtration 571 554 578 Year ended December 31, Operating Expenses (Millions)* 2024 2023 2022 MedSurg $ 1,600 $ 1,438 $ 1,439 Dental Solutions 519 432 419 Health Information Systems 513 504 507 Purification and Filtration 291 235 236 * Operating expenses are comprised of selling, general and administrative expenses and research and development expenses as shown on the Consolidated Statements of Income. Year ended December 31, Operating Performance (Millions) 2024 2023 2022 MedSurg $ 887 $ 1,107 $ 1,061 Dental Solutions 350 442 437 Health Information Systems 431 423 359 Purification and Filtration 94 162 177 Total business segment operating income 1,762 2,134 2,034 Corporate and Unallocated: Amortization expense (349) (365) (373) Other corporate and unallocated (377) (77) 32 Total Corporate and Unallocated (726) (442) (341) Total Company operating income 1,036 1,692 1,693 Interest expense, net 367 — — Other expense/(income), net 64 25 1 Income before income taxes $ 605 $ 1,667 $ 1,692 The following table represents the depreciation amounts reported within the business segment operating income for our reportable segments. The amounts reflected below include both depreciation on property, plant and equipment and equipment held for use. These amounts are included within Cost of Sales and Operating Expenses disclosed in the segment table above. Year ended December 31, (Millions) 2024 2023 2022 MedSurg $ 123 $ 128 $ 144 Dental Solutions 28 23 22 Health Information Systems 5 4 3 Purification and Filtration 40 37 35 Geographic Information: Sales are generally reported within the geographic area that originated the invoice to the Company's customer. Year ended December 31, Net Sales (Millions) 2024 2023 2022 United States $ 4,749 $ 4,603 $ 4,450 International 3,505 3,594 3,680 Worldwide $ 8,254 $ 8,197 $ 8,130 Long-lived assets include property, plant, and equipment, equipment rented to customers, as well as operating lease right-of-use assets. The following table presents long-lived assets based on the physical location of those assets. December 31, Long Lived Assets (Millions) 2024 2023 United States $ 1,046 $ 875 Germany 457 477 Other Countries 356 268 Worldwide $ 1,859 $ 1,620

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 25, 2025, the Company entered into a definitive agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc. for $4.1 billion. The closing of the transaction is expected to be completed by the end of the 2025 calendar year, subject to regulatory approvals and customary closing conditions.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net income	$ 479	$ 1,346	$ 1,343

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	The Company has practices and procedures designed to proactively and comprehensively manage risks from cybersecurity threats. These processes are integrated into the Company’s overall enterprise risk management, as overseen by the Company’s board of directors (the “Board”), primarily through its committees, with its Audit Committee having direct oversight over cybersecurity matters. We identify and assess cybersecurity risk through various technologies, processes and policies that are regularly updated to align with the changing threat landscape, evolving business needs, as well as global regulatory requirements. Our cybersecurity risk mitigation involves a range of threat defense and protection measures such as monitoring of systems, threat containment methods, penetration testing, conducting crises simulations, identity and access management, vulnerability scanning, promoting security and privacy awareness training to our global employees, improving internal processes and following a system of controls, including but not limited to back-up protocols, system restoration processes, and end-point protection on Company devices. We seek to align our cybersecurity risk management with the NIST Cyber Security Framework, as well as industry best practices. Our cybersecurity incident response processes guide the detection, response and recovery from cybersecurity incidents and compliance with regulatory reporting requirements. We engage third-party consultants, external auditors, legal advisors and assessors to help evaluate our cybersecurity program to assist in conducting risk and maturity assessments and as part of our processes for oversight, identification, and management of material risks from cybersecurity threats. Our Third-Party Risk Management program oversees diligence relating to cybersecurity risks from third parties in our supply chain or that have access to our systems, data, or that house such systems or data. The program assesses cybersecurity risks of third-party posture, incidents and data breaches at the third parties identified through such diligence. Also, standard cybersecurity and privacy clauses are included in contracts where appropriate.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	The Company has practices and procedures designed to proactively and comprehensively manage risks from cybersecurity threats. These processes are integrated into the Company’s overall enterprise risk management, as overseen by the Company’s board of directors (the “Board”), primarily through its committees, with its Audit Committee having direct oversight over cybersecurity matters.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Audit Committee of our Board is responsible for the oversight of cybersecurity-related risks. The Audit Committee regularly receives reports from our Chief Information Security Officer (“CISO”), Chief Information and Digital Officer (“CIO”) and other members of management on cybersecurity threat risk management, including security posture improvements, results from third-party assessments, identified risks and progress towards risk-mitigation-related goals. The full Board receives a report from our CISO and other members of management annually.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee of our Board is responsible for the oversight of cybersecurity-related risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee regularly receives reports from our Chief Information Security Officer (“CISO”), Chief Information and Digital Officer (“CIO”) and other members of management on cybersecurity threat risk management, including security posture improvements, results from third-party assessments, identified risks and progress towards risk-mitigation-related goals. The full Board receives a report from our CISO and other members of management annually.
Cybersecurity Risk Role of Management [Text Block]	Our cybersecurity risk management and strategy processes are led by our CISO. The CISO works closely with the CIO, Chief Privacy Officer, and members of the legal team who report to the Chief Legal Affairs Officer to periodically review the cybersecurity program. The CISO has over 25 years of experience in cybersecurity, risk management, and compliance, and has served as the chief information security officer at other organizations. The Company’s CISO oversees the Company’s cybersecurity incident response plan and related processes that are designed to assess and manage material risks from cybersecurity threats. The Company’s CISO also coordinates with the Company’s Legal Affairs team and third parties, such as consultants and legal advisors, to assess and manage material risks from cybersecurity threats. The Company’s CISO is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents pursuant to criteria set forth in the Company’s incident response plan and related processes. Our Disclosure Committee, with the assistance of its Cybersecurity Subcommittee, is responsible for overseeing the establishment and effectiveness of controls and procedures related to the public disclosure of material cybersecurity matters. The Cybersecurity Subcommittee of the Disclosure Committee is comprised of the Controller and Chief Accounting Officer, Treasurer, Chief Legal Affairs Officer, Assistant Secretary, General Auditor, as well as the CISO, CIO and Chief Privacy
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our cybersecurity risk management and strategy processes are led by our CISO. The CISO works closely with the CIO, Chief Privacy Officer, and members of the legal team who report to the Chief Legal Affairs Officer to periodically review the cybersecurity program.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The CISO has over 25 years of experience in cybersecurity, risk management, and compliance, and has served as the chief information security officer at other organizations.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Company’s CISO is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents pursuant to criteria set forth in the Company’s incident response plan and related processes.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and present the historical results of operations, comprehensive income, and cash flows for the years ended December 31, 2024, 2023, and 2022, and financial position as of December 31, 2024 and 2023. Effective April 1, 2024, the Company’s financial statements are presented on a consolidated basis, as the Spin-Off was completed on such date. Prior to April 1, 2024, Solventum was a carve-out business of 3M. The Company's financial statements prior to April 1, 2024 were prepared on a combined basis and were derived from the consolidated financial statements and accounting records of 3M, including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by 3M. The financial statements included in this annual report are referred to as the “Consolidated Financial Statements” for all periods presented. Amounts reported within this annual report are rounded to the nearest million and the sum of the components may not equal the total amount reported due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding. All intercompany transactions and balances within Solventum have been eliminated. These consolidated financial statements include certain transactions with 3M, which are disclosed as related party transactions in Note 16 “Related Parties.”
Foreign currency translation	Foreign currency translation : Local currencies generally are considered the functional currencies outside the United States, and accordingly, the financial statements of these subsidiaries are remeasured as if their functional currency is that of their parent. Assets and liabilities for operations in local-currency environments are translated at month-end exchange rates of the period reported. Income and expense items are translated at average monthly currency exchange rates in effect during the period. Cumulative translation adjustments are recorded as a component of accumulated other comprehensive income (loss) in the consolidated balance sheets.
Use of estimates	Use of estimates : The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions are subject to inherent uncertainties which may result in actual amounts differing from those estimates.
Cash and cash equivalents	Cash and cash equivalents : Cash and cash equivalents included in the Company's consolidated balance sheets includes cash deposits, certificates of deposit, money market and other short-term funds with original maturities of three months or less. In periods prior to Spin-Off, the cash and cash equivalents reflected in the Company's consolidated balance sheet primarily represents cash managed by the Health Care Business as part of 3M's centralized cash program.
Investments	Investments
Equipment held for use	Equipment held for use
Inventories	Inventories : Inventories are stated at the lower of cost or net realizable value (NRV), which is defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Cost is generally determined on a first-in, first-out basis.
Property, plant and equipment	Property, plant and equipment ten twenty three five
Goodwill	Goodwill
Intangible assets	Intangible assets : Intangible asset types include customer-related, patents and other technology-based, tradenames and other intangible assets acquired from an independent party. Intangible assets with a definite life are amortized on a systematic and rational basis (generally straight line) that is representative of the asset’s use. The estimated useful lives vary by category, with customer-related between eleven six four Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable. An impairment loss is recognized when the carrying amount exceeds the estimated undiscounted cash flows from the asset’s or asset group’s ongoing use and eventual disposition. If an impairment is identified, the amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted cash flow analysis.
Restructuring actions	Restructuring actions
Revenue recognition	Revenue recognition : The Company sells a wide range of products to a diversified base of customers around the world. The majority of Solventum’s customer arrangements contain a single performance obligation. The Company also enters into customer arrangements that involve multiple performance obligations (such as rental of equipment and related consumables), software with conterminous post-contract support, and software-as-a-service. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers . Revenue is recognized when control of goods has transferred to customers. For the majority of the Company’s customer arrangements, control transfers to customers at a point-in-time when goods have been delivered as that is generally when legal title, physical possession and the risks and rewards of ownership transfer to the customer. For certain arrangements, specifically software sold with coterminous post-contract support that is integral to maintaining the utility of the software license to the customer and software-as-a-service, control transfers over time as the customer simultaneously receives and consumes the benefits as the Company completes the performance obligation(s). Revenue is recognized at the transaction price which the Company expects to be entitled. The transaction price includes customer rebates, trade promotion funds, and cash discounts, which are accounted for as variable consideration. These sales incentives are recorded as a reduction to revenue at the time of the initial sale based on the most-likely estimate. The most-likely estimate considers historical experience, trend analysis, and projected market conditions in the various markets served. Because the Company serves numerous markets, the sales incentive programs offered vary across businesses, but the most common incentive relates to amounts paid or credited to customers for achieving defined volume levels or growth objectives. There are no material instances where variable consideration is constrained and not recorded at the initial time of sale. Sales, use, value-added, and other excise taxes are not recognized in revenue. The Company has elected to present revenue net of sales taxes and other similar taxes. Product returns are recorded as a reduction to revenue based on anticipated sales returns that occur in the normal course of business. The Company primarily has assurance-type warranties that do not result in separate performance obligations. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. For customers purchasing software from the Company, these performance obligations include providing software licenses with ongoing customer support, installation and training. For medical equipment arrangements, performance obligations include both furnishing a rental unit to a customer as well as delivery of consumables. The Company recognizes revenue from the rental of equipment in accordance with the guidance of ASC 842, Leases . The Company recognizes rental revenue based on the length of time a device is used by the patient/organization, (i) at the contracted rental rate for contracted customers, and (ii) generally, retail price for non-contracted customers. The leases are short-term in nature and are all classified as operating leases. The Company does not have material unfulfilled performance obligation balances for contracts with an original length greater than one year in any years presented. Additionally, the Company does not have material costs related to obtaining a contract with amortization periods greater than one year for any year presented.
Accounts receivable and allowances	Accounts receivable and allowances : Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains allowances for bad debts, which are based on the best estimate of the amount of expected credit losses in existing accounts receivable. The Company determines the allowances based on historical write-off experience informed by industry and regional economic data, and current expectations of future credit losses. The Company reviews the allowances monthly. The allowances for bad debts as well as the provision for credit losses, write-off activity and recoveries for the periods presented are not material.
Research and development	Research and development
Software costs	Software costs : The Company capitalizes direct costs associated with the development of, and external software acquired for use as, internal-use software. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets. Amounts capitalized are amortized over a period of three
Income taxes	Income taxes : Prior to the Spin-Off, the Company was included in the consolidated U.S. federal, state, and foreign income tax returns of 3M, where applicable, through April 1, 2024. The Company's income tax provision for periods 2022, 2023 and the first quarter of 2024 was prepared using the separate return method. The calculation of income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations. As a result, transactions included in the consolidated financial statements of 3M may not be included in the Company's consolidated financial statements. Similarly, the tax treatment of certain items reflected in the Company's consolidated financial statements may not be reflected in the consolidated financial statements and tax returns of 3M. Therefore, items such as net operating losses, credit carryforwards, and valuation allowances may exist in the Company's standalone financial statements that may or may not exist in 3M’s consolidated financial statements. After the Spin-Off, the Company will file tax returns on its own behalf, and its income tax provision is prepared on a standalone basis. As a result, its deferred taxes and effective tax rate for 2024 may differ from those in the historical periods prior to Spin-Off. In jurisdictions where the Company has been included in income tax returns filed by 3M, income taxes currently payable will be deemed to have been remitted to 3M, in cash, in the period the liability arose and income taxes currently receivable are deemed to have been received from the Parent in the period that a refund could have been recognized. Adjustments to the recorded payable that derive from the Company's current year activity are recorded through current tax expenses and the ending adjusted payable/receivable is settled through “Net parent investment” on the consolidated balance sheets. Current obligations for tax in jurisdictions where the Company does not file a consolidated tax return with 3M, including certain foreign and certain U.S. state tax jurisdictions, are recorded as accrued liabilities within “Other current liabilities” on the consolidated balance sheets. The effects of tax adjustments and settlements with taxing authorities are presented in our consolidated financial statements in the period to which they relate. Uncertain tax positions that meet the more likely than not recognition threshold are measured to determine the amount of tax benefit to recognize in the consolidated financial statements. An uncertain tax position is measured at the largest amount of benefit that the Company believes has a greater than 50% likelihood of realization upon settlement. Tax benefits not meeting the measurement or realization criteria represent unrecognized tax benefits. The Company recognizes interest and penalties related to income tax matters as a component of “Provision for income taxes” in the consolidated statements of income. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their respective tax bases, as well as from net operating loss and tax credit carryforwards. The deferred income tax balances are stated at enacted tax rates expected to be in effect when those taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. We evaluate the recoverability of these future tax deductions and tax credits by evaluating all available positive and negative evidence, specifically assessing the adequacy of future expected taxable income from all sources, including reversal of existing taxable temporary differences, forecasted operating earnings, and available tax planning strategies. To the extent we consider it more likely than not that a deferred tax asset will not be recovered, a valuation allowance is established.
Stock-based compensation	Stock-based compensation : The Company recognizes compensation expense for its stock-based compensation awards, which include stock options, restricted stock units (RSUs), and performance share units (PSUs). In accordance with ASC 718, Compensation—Stock Compensation
Comprehensive income	Comprehensive income : Total comprehensive income and the components of accumulated other comprehensive income (loss) are presented in the consolidated statements of comprehensive income and the consolidated statements of changes in equity. Accumulated other comprehensive income (loss) is composed of foreign currency translation effects, defined benefit pension adjustments and gains/losses from cash flow hedging activity.
Fair value measurements	Fair value measurements: Solventum follows ASC 820, Fair Value Measurements , with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under the standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying value of the Company's accounts receivable, accounts payable, and accrued expenses approximate their fair value due to the short period of time to maturity or repayment.
Leases	Leases : Solventum determines if an arrangement is a lease upon inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The right to control the use of an asset includes the right to obtain substantially all of the economic benefits of the underlying asset and the right to direct how and for what purpose the asset is used. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using Solventum’s incremental borrowing rate at lease commencement. Solventum determines the incremental borrowing rate for leases using a portfolio approach based primarily on the lease term and the economic environment of the applicable country or region. As a lessee, the Company leases distribution centers, office space, land, and equipment. Certain lease agreements include rental payments adjusted annually based on changes in an inflation index. The Company’s leases do not contain material residual value guarantees or material restrictive covenants. Lease expense is recognized on a straight-line basis over the lease term. Certain leases include one or more options to renew, with terms that can extend the lease term up to five years. The Company includes options to renew the lease as part of the right-of-use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options. For the measurement and classification of its lease agreements, the Company groups lease and non-lease components into a single lease component for all underlying asset classes. Variable lease payments primarily include payments for non-lease components, such as maintenance costs, payments for leased assets used beyond their noncancellable lease term as adjusted for contractual options to terminate or renew, additional payments related to a subsequent adjustment in an inflation index, and payments for non-components such as sales tax. Certain leases contain immaterial variable lease payments based on number of units produced.
Leases	Leases : Solventum determines if an arrangement is a lease upon inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The right to control the use of an asset includes the right to obtain substantially all of the economic benefits of the underlying asset and the right to direct how and for what purpose the asset is used. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using Solventum’s incremental borrowing rate at lease commencement. Solventum determines the incremental borrowing rate for leases using a portfolio approach based primarily on the lease term and the economic environment of the applicable country or region. As a lessee, the Company leases distribution centers, office space, land, and equipment. Certain lease agreements include rental payments adjusted annually based on changes in an inflation index. The Company’s leases do not contain material residual value guarantees or material restrictive covenants. Lease expense is recognized on a straight-line basis over the lease term. Certain leases include one or more options to renew, with terms that can extend the lease term up to five years. The Company includes options to renew the lease as part of the right-of-use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options. For the measurement and classification of its lease agreements, the Company groups lease and non-lease components into a single lease component for all underlying asset classes. Variable lease payments primarily include payments for non-lease components, such as maintenance costs, payments for leased assets used beyond their noncancellable lease term as adjusted for contractual options to terminate or renew, additional payments related to a subsequent adjustment in an inflation index, and payments for non-components such as sales tax. Certain leases contain immaterial variable lease payments based on number of units produced.
New Accounting Pronouncements	New Accounting Pronouncements The table below provides summaries of recently adopted financial accounting standards and recently issued financial accounting standards. Standard Relevant Description Effective Date for Solventum Impact of Adoption ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Issued in November 2023. Requires public entities to expand on segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Year-end December 31, 2024 The Company has assessed the impact of the updated standard and has included expanded disclosures within the business segment footnote. ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Issued in December 2023. Requires disaggregated information about a Company's effective tax rate reconciliation as well as information on income taxes paid. Year-end December 31, 2025 The Company is currently assessing the impact that the updated standard will have on financial statement disclosures. ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses Issued in November 2024. Requires additional disclosure of the nature of expenses included in the income statement. Year-end December 31, 2026 The Company is currently assessing the impact that the updated standard will have on financial statement disclosures.
Commitments and Contingencies	Process for Disclosure and Recording of Insurance Receivables Related to Legal Proceedings The Company estimates insurance receivables based on an analysis of the terms of its numerous policies, including their exclusions, pertinent case law interpreting comparable policies, its experience with similar claims, and assessment of the nature of the claim and remaining coverage, and records an amount it has concluded is recognizable and expects to receive in light of the loss recovery and/or gain contingency models under ASC 450, ASC 610-30, and related guidance. For those insured legal proceedings for which the Company has recorded an accrued liability in its financial statements, the Company also records receivables for the amount of insurance that it concludes as recognizable from the Company’s insurance program. For those insured matters for which the Company has not recorded an accrued liability because the liability is not probable or the amount of the liability is not estimable, or both, but for which the Company has incurred an expense in defending itself, the Company records receivables for the amount of insurance that it concludes as recognizable for the expense incurred.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of Accounting Standards Update and Change in Accounting Principle	The table below provides summaries of recently adopted financial accounting standards and recently issued financial accounting standards. Standard Relevant Description Effective Date for Solventum Impact of Adoption ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Issued in November 2023. Requires public entities to expand on segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Year-end December 31, 2024 The Company has assessed the impact of the updated standard and has included expanded disclosures within the business segment footnote. ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Issued in December 2023. Requires disaggregated information about a Company's effective tax rate reconciliation as well as information on income taxes paid. Year-end December 31, 2025 The Company is currently assessing the impact that the updated standard will have on financial statement disclosures. ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses Issued in November 2024. Requires additional disclosure of the nature of expenses included in the income statement. Year-end December 31, 2026 The Company is currently assessing the impact that the updated standard will have on financial statement disclosures.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill Segment	The goodwill balance by business segment is as follows: (Millions) MedSurg Dental Solutions Health Information Systems Purification and Filtration Total Balance as of December 31, 2022 $ 3,606 $ 452 $ 871 $ 1,505 $ 6,434 Divestiture — (4) — — (4) Translation impact 79 10 2 14 105 Balance as of December 31, 2023 3,685 458 873 1,519 6,535 Translation impact (88) (19) (2) (49) (158) Balance as of December 31, 2024 $ 3,597 $ 439 $ 871 $ 1,470 $ 6,377
Schedule of Finite-Lived Intangible Assets	The carrying amount and accumulated amortization of acquired finite-lived intangible assets, in addition to the balance of non-amortizable intangible assets are as follows: December 31, December 31, (Millions) 2024 2023 Customer related intangible assets $ 2,720 $ 2,734 Patents and other technology-based intangible assets 1,895 1,897 Tradenames and other amortizable intangible assets 729 705 Total gross carrying amount 5,344 5,336 Accumulated amortization — customer related (1,208) (1,081) Accumulated amortization — patents and other technology-based (1,224) (1,055) Accumulated amortization — tradenames and other (368) (323) Total accumulated amortization (2,800) (2,459) Total finite-lived intangible assets — net 2,544 2,877 Indefinite lived intangible assets — 25 Total intangible assets — net $ 2,544 $ 2,902
Schedule of Indefinite-Lived Intangible Assets	The carrying amount and accumulated amortization of acquired finite-lived intangible assets, in addition to the balance of non-amortizable intangible assets are as follows: December 31, December 31, (Millions) 2024 2023 Customer related intangible assets $ 2,720 $ 2,734 Patents and other technology-based intangible assets 1,895 1,897 Tradenames and other amortizable intangible assets 729 705 Total gross carrying amount 5,344 5,336 Accumulated amortization — customer related (1,208) (1,081) Accumulated amortization — patents and other technology-based (1,224) (1,055) Accumulated amortization — tradenames and other (368) (323) Total accumulated amortization (2,800) (2,459) Total finite-lived intangible assets — net 2,544 2,877 Indefinite lived intangible assets — 25 Total intangible assets — net $ 2,544 $ 2,902
Schedule of Finite-Lived Intangible Assets Amortization Expense	Amortization expense was as follows: Year ended December 31, (Millions) 2024 2023 2022 Amortization expense $ 349 $ 365 $ 373
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Expected amortization expense for acquired amortizable intangible assets recorded as of December 31, 2024 is as follows: (Millions) 2025 2026 2027 2028 2029 After 2029 Amortization expense $ 324 $ 319 $ 314 $ 309 $ 272 $ 1,006

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Schedule of Other Current Liabilities	Other current liabilities included in the consolidated balance sheets consist of the following: December 31, December 31, (Millions) 2024 2023 Other current liabilities Accrued compensation $ 281 $ 209 Accrued taxes 122 106 Accrued rebates 146 206 Accrued interest 114 — Other 378 156 Total other current liabilities $ 1,041 $ 677

Property, Plant, and Equipmen_2

Property, Plant, and Equipment - Net (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment - net consisted of the following: December 31, December 31, (Millions) 2024 2023 Property, plant and equipment - at cost Buildings and leasehold improvements $ 956 $ 937 Machinery and equipment 2,150 2,081 Construction in progress 504 320 Gross property, plant and equipment 3,610 3,338 Accumulated depreciation (1,988) (1,881) Property, plant and equipment - net $ 1,622 $ 1,457 Depreciation expense consisted of the following: Year ended December 31, (Millions) 2024 2023 2022 Depreciation expense $ 181 $ 164 $ 177

Comprehensive Income Informat_2

Comprehensive Income Information (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The table below presents the changes in accumulated other comprehensive income (loss) (“AOCI”), including the reclassifications out of AOCI by component: (Millions) Cumulative Translation Adjustment Defined Benefit Pension Cash Flow Hedging Total Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2021, net of tax $ (173) $ (27) $ — $ (200) Other comprehensive income (loss), before tax: Amounts before reclassifications (331) 45 — (286) Amounts reclassified out — 2 — 2 Total other comprehensive income (loss), before tax (331) 47 — (284) Tax effect — (13) — (13) Total other comprehensive income (loss), net of tax (331) 34 — (297) Transfers from 3M, net of tax — — — — Balance at December 31, 2022, net of tax: $ (504) $ 7 $ — $ (497) Other comprehensive income (loss), before tax: Amounts before reclassifications 157 (50) — 107 Amounts reclassified out — — — — Total other comprehensive income (loss), before tax 157 (50) — 107 Tax effect — 17 — 17 Total other comprehensive income (loss), net of tax 157 (33) — 124 Transfers from 3M, net of tax — 36 — 36 Balance at December 31, 2023, net of tax: $ (347) $ 10 $ — $ (337) Other comprehensive income (loss), before tax: Amounts before reclassifications (239) (44) 24 (259) Amounts reclassified out 38 39 2 79 Total other comprehensive income (loss), before tax (201) (5) 26 (180) Tax effect (2) — (6) (8) Total other comprehensive income (loss), net of tax (203) (5) 20 (188) Transfers from 3M, net of tax — (531) — (531) Balance at December 31, 2024, net of tax $ (550) $ (526) $ 20 $ (1,056)

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Income Taxes	Income (loss) before income taxes consisted of the following: (Millions) 2024 2023 2022 United States $ (47) $ 1,221 $ 1,276 International 652 446 416 Total $ 605 $ 1,667 $ 1,692
Schedule of Provision (Benefit) for Income Taxes	Provision (benefit) for income taxes consisted of the following: (Millions) 2024 2023 2022 Currently payable Federal $ 112 $ 148 $ 355 State 25 44 53 International 145 271 82 Deferred Federal (134) (8) (127) State (11) (9) (8) International (10) (125) (6) Total $ 127 $ 321 $ 349
Schedule of Components of Deferred Tax Assets and Liabilities	Components of deferred tax assets and (liabilities) are comprised of the following: (Millions) 2024 2023 Deferred tax assets: Miscellaneous accruals $ 42 $ 52 Accrued compensation 159 102 Net operating/capital loss carryforward 55 95 Disallowed interest carryforwards 14 — Foreign tax credits 35 52 Advanced royalties — 26 Research and experimentation capitalization 129 213 Lease liabilities 32 16 Other deferred tax assets 20 37 Gross deferred tax assets 486 593 Valuation allowance (33) (56) Total deferred tax assets 453 537 Deferred tax liabilities: Property, plant, and equipment (78) (108) Intangible assets (278) (324) Right-of-use assets (33) (16) Total deferred tax liabilities (389) (448) Net deferred tax asset (liability) $ 64 $ 89
Schedule of Reconciliation of Effective Income Tax Rate	A reconciliation of the U.S. federal statutory income tax rate to Solventum's worldwide effective income tax rate is provided below: 2024 2023 2022 U.S. Statutory income tax rate 21.0 % 21.0 % 21.0 % State income taxes - net of federal benefit 1.8 1.7 2.1 International income taxes - net (7.0) (1.3) (1.7) Global Intangible Low Taxed Income (GILTI) 4.2 0.8 0.7 Foreign Derived Intangible Income (FDII) (3.3) (2.2) (2.5) U.S. research and development credit (4.1) (1.2) (1.8) Reserves for tax contingencies (1.4) (4.1) 0.6 Tax impact of legal entity restructuring 4.7 2.3 — Changes in valuation allowance 2.6 1.4 0.7 Deferred rate change 0.9 0.1 (0.3) All other - net 1.5 0.8 1.8 Effective income tax rate 20.9 % 19.3 % 20.6 %
Schedule of Unrecognized Tax Benefits	A rollforward of unrecognized tax benefits (“UTB”) is as follows: (Millions) 2024 2023 2022 Gross UTB Balance at January 1 $ 205 $ 307 $ 308 Additions based on tax positions related to the current year 4 22 18 Additions for tax positions of prior years — 17 17 Additions related to recent acquisitions — — — Reductions for tax positions of prior years (64) (35) (19) Settlements — — — Reductions due to lapse of applicable statute of limitations (8) (74) (10) Reductions for amounts recorded to net parent investment — (32) (7) Gross UTB Balance at December 31 $ 137 $ 205 $ 307

Long-Term Debt and Short-Term_2

Long-Term Debt and Short-Term Borrowings (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long -Term Debt and Short-Term Debt	Carrying value includes the impact of debt issuance costs. There were no long-term debt or short-term borrowings as of December 31, 2023. Long-term debt and short-term borrowings as of December 31, 2024 consisted of the following: (Millions) Currency/ Fixed vs. Floating Effective Interest Rate Final Maturity Date Carrying Value Description December 31, 2024 Eighteen USD Floating 6.13 % 2025 $ 200 Three USD Floating 6.13 2027 979 $1 billion 5.45 percent three USD Fixed 5.40 2027 995 $1.5 billion 5.40 percent five USD Fixed 5.39 2029 1,487 $1 billion 5.45 percent seven USD Fixed 5.45 2031 990 $1.65 billion 5.60 percent ten USD Fixed 5.63 2034 1,636 $1.25 billion 5.90 percent thirty USD Fixed 6.05 2054 1,231 $500 million 6.00 percent forty USD Fixed 6.17 2064 492 Other borrowings — Total long-term debt 8,010 Less: current portion of long-term debt 200 Long-term debt (excluding current portion) $ 7,810
Schedule of Maturities of Long-Term Debt	The maturities of long-term debt for the periods subsequent to December 31, 2024 are as follows (in millions): 2025 2026 2027 2028 2029 After 2029 Total $ 200 $ — $ 1,980 $ — $ 1,500 $ 4,400 $ 8,080

Pension and Postretirement Be_2

Pension and Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Schedule of Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan	The following tables include a reconciliation of the beginning and ending balances of the Company-sponsored benefit obligations and the fair value of plan assets, as well as a summary of the related amounts recognized in the consolidated balance sheets as of December 31 of the respective years: Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2024 2023 2024 2023 Change in benefit obligation Benefit obligation at beginning of year $ — $ — $ 519 $ 105 $ — $ — Service cost 20 — 18 5 3 — Interest cost 70 — 19 7 9 — Participant contributions — — 1 — — — Foreign exchange rate changes — — (36) 19 — — Actuarial (gain) loss (9) — (4) 70 (10) — Benefit payments (96) — (10) (8) (11) — Settlements, curtailments, special termination benefits and other (2) — 1 — (1) — Transfers from 3M 1,874 — 103 321 260 — Benefit obligation at end of year $ 1,857 $ — $ 611 $ 519 $ 250 $ — Change in plan assets Fair value of plan assets at beginning of year $ — $ — $ 367 $ 9 $ — $ — Actual return on plan assets 48 — 15 21 3 — Company contributions 3 — 16 11 1 — Participant contributions — — 1 — — — Foreign exchange rate changes — — (28) 16 — — Benefit payments (96) — (10) (8) (11) — Settlements, curtailments, special termination benefits and other (2) — — — (1) — Transfers from 3M 1,832 — 110 318 140 — Fair value of plan assets at end of year 1,785 — 471 367 132 — Funded status at end of year $ (72) $ — $ (140) $ (152) $ (118) $ —
Schedule of Amounts Recognized in Balance Sheet	Amounts recognized in the Consolidated Balance Sheet as of December 31, (Millions) Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2024 2023 2024 2023 Other assets $ — $ — $ 18 $ 9 $ — $ — Accrued benefit cost Current liabilities (2) — (3) (1) (1) — Non-current liabilities (70) — (155) (160) (117) — Ending balance $ (72) $ — $ (140) $ (152) $ (118) $ —
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	Amounts recognized in accumulated other comprehensive (income) loss as of December 31, (Millions) Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2024 2023 2024 2023 Net actuarial loss (gain) 658 — 4 (11) 47 — Prior service cost (credit) — — — — (15) — Ending balance $ 658 $ — $ 4 $ (11) $ 32 $ —
Schedule of Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets	The following table summarizes the total accumulated benefit obligations, the accumulated benefit obligations and fair value of plan assets for defined benefit pension plans with accumulated benefit obligations in excess of plan assets, and the projected benefit obligation and fair value of plan assets for defined benefit pension plans with projected benefit obligation in excess of plan assets as of December 31, 2024: Qualified and Non-qualified Pension Plans United States International (Millions) 2024 2023 2024 2023 Accumulated benefit obligation $ 1,775 $ — $ 558 $ 460 Plans with accumulated benefit obligation in excess of plan assets Accumulated benefit obligation $ 22 $ — $ 405 $ 398 Fair value of plan assets — — 285 294 Plans with projected benefit obligation in excess of plan assets Projected benefit obligation $ 1,857 $ — $ 452 $ 476 Fair value of plan assets 1,785 — 294 316
Schedule of Net Benefit Costs	Components of net periodic benefit cost and other supplemental information for the respective years ended December 31 are as follows: Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2022 2024 2023 2022 2024 2023 2022 Net periodic benefit cost (benefit) Operating expense Service cost $ 20 $ — $ — $ 18 $ 5 $ 6 $ 3 $ — $ — Non-operating expense Interest cost 70 — — 19 7 2 9 — — Expected return on plan assets (103) — — (20) (3) (1) (7) — — Amortization of prior service benefit (2) — — — — — (3) — — Amortization of net actuarial loss 40 — — — — — 3 — — Settlements, curtailments, special termination benefits and other 1 — — 1 — 2 — — — Total non-operating expense (benefit) 6 — — — 4 3 2 — — Total net periodic benefit cost (benefit) $ 26 $ — $ — $ 18 $ 9 $ 9 $ 5 $ — $ — Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Amortization of transition asset $ — $ — $ — $ — $ — $ (1) $ — $ — $ — Amortization of prior service benefit 2 — — — — — 3 — — Net actuarial (gain) loss 46 — — 1 52 (43) (6) — — Amortization of net actuarial loss (40) — — — 1 (1) (3) — — Foreign currency — — — — (2) (2) — — — Settlements, curtailments, special termination benefits and other (1) — — — (1) — — — — Total recognized in other comprehensive (income) loss 7 — — 1 50 (47) (6) — — Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 33 $ — $ — $ 19 $ 59 $ (38) $ (1) $ — $ — Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2022 2024 2023 2022 2024 2023 2022 Discount rate - service cost 5.31 % — % — % 3.43 % 4.88 % 2.18 % 5.30 % — % — % Discount rate - interest cost 5.20 — — 3.37 5.24 4.53 5.14 — — Expected return on assets 7.75 — — 4.69 4.61 6.53 7.85 — — Compensation rate increase 3.77 — — 2.89 2.89 3.00 N/A N/A N/A
Schedule of Defined Benefit Plan, Assumptions	Weighted-Average Assumptions Used to Determine Benefit Obligations as of December 31: Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International 2024 2023 2022 2024 2023 2022 2024 2023 2022 Discount rate 5.64 % — % — % 3.54 % 3.30 % 4.59 % 5.60 % — % — % Compensation rate increase 3.77 % — % — % 2.88 % 2.90 % 3.22 % N/A N/A N/A
Schedule of Expected Benefit Payments	The following table provides the estimated pension and postretirement benefit payments that are payable from the plans to participants: Qualified and Non-qualified Pension Benefits Postretirement Benefits (Millions) United States International 2025 Benefit payments $ 164 $ 23 $ 20 2026 Benefit payments 159 22 21 2027 Benefit payments 157 24 21 2028 Benefit payments 156 26 22 2029 Benefit payments 154 30 22 Next five years 737 160 104
Schedule of Allocation of Plan Assets	The fair values of the assets held by the U.S. pension and postretirement benefit plans by asset class are as follows: Fair Value Measurements Using Inputs Considered as Investments Measured at Net Asset Value* Fair Value at December 31, Level 1 Level 2 Level 3 (Millions) 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 U.S. Pension Plans Cash and cash equivalents $ 333 $ — $ — $ — $ — $ — $ — $ — $ 333 $ — Equities 180 — — — — — — — 180 — Fixed income 35 — 701 — — — — — 736 — Absolute return — — — — — — 245 — 245 — Private equity — — — — — — 283 — 283 — Total $ 548 $ — $ 701 $ — $ — $ — $ 528 $ — $ 1,777 $ — Other items to reconcile to fair value of plan assets 8 — Fair value of plan assets $ 1,785 $ — Postretirement Benefit Plans Cash and cash equivalents $ 25 $ — $ — $ — $ — $ — $ — $ — $ 25 $ — Equities 13 — — — — — — — 13 — Fixed income 3 — 52 — — — — — 55 — Absolute return — — — — — — 18 — 18 — Private equity — — — — — — 21 — 21 — Total $ 41 $ — $ 52 $ — $ — $ — $ 39 $ — $ 132 $ — Other items to reconcile to fair value of plan assets — Fair value of plan assets $ 132 $ — * I n accordance with ASC 820-10, certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the fair value of the underlying assets owned by the fund, minus its liabilities then divided by the number of units outstanding and is determined by the investment manager or custodian of the fund. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the fair value of plan assets. The fair values of the assets held by the international pension plans by asset class are as follows: Fair Value Measurements Using Inputs Considered as Investments Measured at Net Asset Value* Fair Value at December 31, Level 1 Level 2 Level 3 (Millions) 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Cash and cash equivalents $ 3 $ 2 $ — $ — $ — $ — $ — $ — $ 3 $ 2 Equities 5 7 29 23 — — 19 24 53 54 Fixed income 6 6 217 188 — — 20 31 243 225 Absolute return — — — — 33 28 3 10 36 38 Private equity — — — — — — 48 47 48 47 Total $ 14 $ 15 $ 246 $ 211 $ 33 $ 28 $ 90 $ 112 $ 383 $ 366 Other items to reconcile to fair value of plan assets 88 1 Fair value of plan assets $ 471 $ 367 *In accordance with ASC 820-10, certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the fair value of the underlying assets owned by the fund, minus its liabilities, then divided by the number of units outstanding, and is determined by the investment manager or custodian of the fund. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the fair value of plan assets.

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Gains (Loss) on Derivative Instruments Designated as Hedges	The amount of pretax gain (loss) recognized in other comprehensive income (loss) related to derivative instruments designated as cash flow hedges is provided in the following table. Pretax Gain (Loss) Recognized in Other Comprehensive Income (Loss) on Derivative Year ended December 31, (Millions) 2024 2023 2022 Foreign currency forward contracts $ 26 $ — $ —
Schedule of Location and Fair Value of Derivative Instruments	The following tables summarize the fair value of Solventum’s derivative instruments and their location in the consolidated balance sheets. Notional amounts below are presented at period end foreign exchange rates. Gross Notional Amount Assets Liabilities (Millions) Location Fair Value Amount Location Fair Value Amount December 31, December 31, December 31, December 31, December 31, December 31, 2024 2023 2024 2023 2024 2023 Derivatives designated as hedging instruments Foreign currency forward contracts $ 355 $ — Other current assets $ 17 $ — Other current liabilities $ — $ — Foreign currency forward contracts 157 — Other assets 6 — Other liabilities — — Cross-currency swaps 380 $ — Other assets 10 $ — Other liabilities — $ — Total derivatives designated as hedging instruments $ 892 $ — $ 33 $ — $ — $ — Derivatives not designated as hedging instruments Foreign currency forward contracts $ 397 $ — Other current assets $ — $ — Other current liabilities $ — $ — Total derivatives not designated as hedging instruments $ 397 $ — $ — $ — $ — $ — Total derivative instruments $ 1,289 $ — $ 33 $ — $ — $ —
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	The amount of pretax gain (loss) recognized in other comprehensive income (loss) related to derivative instruments designated as net investment hedges is provided in the following table. Pretax Gain (Loss) Recognized as Cumulative Translation within Other Comprehensive Income (Loss) Year ended December 31, (Millions) 2024 2023 2022 Cross-currency swaps $ 10 $ — $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Lease Costs	(Millions) 2024 2023 2022 Operating lease cost $ 75 $ 28 $ 32 Supplemental cash flow information related to operating lease is as follows: (Millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: $ 76 $ 29 $ 31 Right of use assets obtained in exchange for operating lease liabilities: $ 148 $ 37 $ 14
Schedule of Assets And Liabilities, Lessee	Supplemental balance sheet, lease term and discount rate information related to operating leases is as follows: December 31, (Millions unless noted) Location on face of Balance Sheet 2024 2023 Operating leases: Operating lease right of use assets Other assets $ 176 $ 98 Current operating lease liabilities Other current liabilities 87 29 Noncurrent operating lease liabilities Other liabilities 86 69 Total operating lease liabilities $ 173 $ 98 Weighted average remaining lease term (in years): 2.9 4.3 Weighted average discount rate: 4.2 % 2.9 %
Schedule of Lessee, Operating Lease, Liability, to be Paid, Maturity	Maturities of operating leases as of December 31, 2024 are as follows: (Millions) 2025 $ 89 2026 44 2027 22 2028 10 2029 4 After 2029 7 Total expected lease payments 176 Less: Amounts representing interest (3) Present value of future minimum lease payments $ 173

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The related restructuring charges for periods presented were recorded in the consolidated statement of income as follows: (Millions) 2024 Cost of product $ 17 Cost of software and rentals 2 Selling, general and administrative expenses 36 Research and development expenses 7 Total operating income impact $ 62
Schedule of Restructuring Reserve by Type of Cost	Restructuring actions, including cash and non-cash impacts, are as follows: (Millions) Employee Termination Benefits Asset-Related and Other Total Expense incurred in 2024 $ 46 $ 16 $ 62 Non-cash changes — (8) (8) Cash payments (1) — (1) Accrued liabilities as of December 31, 2024 $ 45 $ 8 $ 53

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The computations for basic and diluted EPS are as follows: Year ended December 31, (Amounts in millions, except per share amounts) 2024 2023 2022 Numerator: Net income $ 479 $ 1,346 $ 1,343 Denominator: Weighted average common shares outstanding – basic 173.2 172.7 172.7 Dilution associated with stock-based compensation plans 0.5 — — Weighted average common shares outstanding – diluted 173.7 172.7 172.7 Basic earnings per share $ 2.77 $ 7.79 $ 7.78 Diluted earnings per share $ 2.76 $ 7.79 $ 7.78

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Amounts recognized in the consolidated financial statements related to stock-based compensation awards, including stock options, RSUs, and PSUs, are provided in the following table. Total stock-based compensation expense recognized in cost of product and cost of software and rentals has been combined in the table below as cost of sales. Capitalized stock-based compensation amounts were not material. Year ended December 31, (Millions) 2024 2023 2022 Cost of sales $ 14 $ 8 $ 8 Selling, general and administrative expenses 82 23 20 Research and development expenses 16 8 9 Stock-based compensation expenses 112 39 37 Income tax benefits (18) (9) (9) Stock-based compensation expenses, net of tax $ 94 $ 30 $ 28
Schedule of Stock Option Activity	The following table summarizes stock option activity: (Options in thousands) Number of Options Weighted Average Exercise Price Weighted Average Aggregate Outstanding as of April 1, 2024 (1) 4,073 $ 106.45 Granted — — Exercised — — Forfeited (35) 86.46 Expired (47) 106.52 Outstanding as of December 31, 2024 3,991 106.63 55 $ — Exercisable as of December 31, 2024 3,571 108.56 51 — Expected to vest 419 $ 90.30 90 $ — (1) Solventum common stock began trading on the New York Stock Exchange (NYSE) on April 1, 2024. The shares outstanding as of April 1 2024 pertain to 3M Company equity-based awards issued by 3M in prior periods to employees and non-employee directors of the Company that were converted to Solventum equity-based awards as part of the Spin-Off.
Schedule of Restricted Stock Units Activity	The following table summarizes the RSU activity: (Units in thousands) Number of Shares Weighted Average Grant Date Fair Value Nonvested as of April 1, 2024 (1) 1,304 $ 76.93 Granted 2,305 62.77 Vested (136) 67.12 Forfeited (136) 68.54 Nonvested as of December 31, 2024 3,337 $ 67.89 (1) Solventum common stock began trading on the New York Stock Exchange (NYSE) on April 1, 2024. The shares outstanding as of April 1, 2024 pertain to 3M Company equity-based awards issued by 3M in prior periods to employees and non-employee directors of the Company that were converted to Solventum equity-based awards as part of the Spin-Off. (in millions, except per-share amounts) 2024 2023 2022 Weighted average grant date fair value of restricted stock units (per unit) that were granted $ 62.77 $ — $ — Total fair value of restricted stock units that vested $ 9 $ — $ —

Related Parties (Tables)

Related Parties (Tables)	12 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	3M expense allocations were recorded in the consolidated statements of income within the following captions: Twelve months ended December 31, (Millions) 2024 2023 2022 Costs of product $ 15 $ 89 $ 74 Costs of software and rentals — — — Selling, general and administrative expenses 177 678 617 Research and development expenses 28 86 87 Total $ 220 $ 853 $ 778 The Company had the following transactions with 3M and its affiliates, primarily in connection with the Transition Services Agreement, Transition Distribution Services Agreement, Transition Contract Manufacturing Agreements and Master Supply Agreements, reported in the Company’s consolidated financial statements: Year ended December 31, (Amounts in millions) 2024 2023 Net sales of product $ 50 $ — Cost of product 357 — Selling, general and administrative expenses 202 — Research and development expenses 8 — The reconciliation of net transfers to 3M between the consolidated changes in equity and the consolidated statements of cash flows are as follows: Year ended December 31, (Millions) 2024 2023 2022 Net transfers to 3M on the consolidated changes in equity $ (8,571) $ (1,582) $ (1,363) Stock compensation expense (4) (39) (37) Multiemployer pension expense (5) (32) (56) Net balances transferred from 3M 329 100 — Net transfers to 3M on the consolidated statements of cash flows $ (8,251) $ (1,553) $ (1,456)

Business Segments (Tables)

Business Segments (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule Of Business Segment Description	Business Segment Offerings: Business Segment Representative revenue-generating activities, products or services MedSurg • P rovider of a broad range of innovative, advanced wound care and surgical solutions that are intended to accelerate healing, prevent complications and lower the total cost of care globally. Dental Solutions • Provider of a comprehensive suite of dental and orthodontic products that span the life of the tooth, which are intended to address clinical needs in prevention, restoration, replacement, and malocclusion correction. Health Information Systems • P rovider of software solutions and services that are designed to create more time for clinicians to care for patients, improve accuracy in healthcare reimbursement, and support the shift to value-based care. Purification and Filtration • Provider of filters and membranes for use in the manufacturing of biopharmaceutical and medical technologies, microelectronics and food and beverage products, as well as filtration for cleaner drinking water.
Schedule of Segment Reporting Information, by Segment	Year ended December 31, Net Sales (Millions) 2024 2023 2022 MedSurg $ 4,637 $ 4,632 $ 4,585 Dental Solutions 1,295 1,329 1,327 Health Information Systems 1,306 1,285 1,227 Purification and Filtration 956 951 991 Corporate and Unallocated 59 — — Total Company $ 8,254 $ 8,197 $ 8,130 Year ended December 31, Cost of Sales (Millions) 2024 2023 2022 MedSurg $ 2,151 $ 2,087 $ 2,085 Dental Solutions 425 455 471 Health Information Systems 361 358 361 Purification and Filtration 571 554 578 Year ended December 31, Operating Expenses (Millions)* 2024 2023 2022 MedSurg $ 1,600 $ 1,438 $ 1,439 Dental Solutions 519 432 419 Health Information Systems 513 504 507 Purification and Filtration 291 235 236 * Operating expenses are comprised of selling, general and administrative expenses and research and development expenses as shown on the Consolidated Statements of Income. Year ended December 31, Operating Performance (Millions) 2024 2023 2022 MedSurg $ 887 $ 1,107 $ 1,061 Dental Solutions 350 442 437 Health Information Systems 431 423 359 Purification and Filtration 94 162 177 Total business segment operating income 1,762 2,134 2,034 Corporate and Unallocated: Amortization expense (349) (365) (373) Other corporate and unallocated (377) (77) 32 Total Corporate and Unallocated (726) (442) (341) Total Company operating income 1,036 1,692 1,693 Interest expense, net 367 — — Other expense/(income), net 64 25 1 Income before income taxes $ 605 $ 1,667 $ 1,692 The following table represents the depreciation amounts reported within the business segment operating income for our reportable segments. The amounts reflected below include both depreciation on property, plant and equipment and equipment held for use. These amounts are included within Cost of Sales and Operating Expenses disclosed in the segment table above. Year ended December 31, (Millions) 2024 2023 2022 MedSurg $ 123 $ 128 $ 144 Dental Solutions 28 23 22 Health Information Systems 5 4 3 Purification and Filtration 40 37 35
Schedule of Revenue from External Customers by Geographic Areas	Sales are generally reported within the geographic area that originated the invoice to the Company's customer. Year ended December 31, Net Sales (Millions) 2024 2023 2022 United States $ 4,749 $ 4,603 $ 4,450 International 3,505 3,594 3,680 Worldwide $ 8,254 $ 8,197 $ 8,130
Schedule of Long-Lived Assets by Geographic Areas	The following table presents long-lived assets based on the physical location of those assets. December 31, Long Lived Assets (Millions) 2024 2023 United States $ 1,046 $ 875 Germany 457 477 Other Countries 356 268 Worldwide $ 1,859 $ 1,620

Significant Accounting Polici_4

Significant Accounting Policies (Details) $ in Millions		12 Months Ended
	Apr. 01, 2024 shares	Dec. 31, 2024 USD ($) option operatingSegment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Accounting Policies [Line Items]
Spinoff transaction, percent of shares outstanding distributed	80.10%
Issuance of common stock in connection with Spin-Off and reclassification of net parent investment (in shares) | shares	172,709,505
Number of operating segments | operatingSegment		4
Depreciation expense		$ 181	$ 164	$ 177
Number of renewal options | option		1
Lessee, operating lease, renewal term		5 years
Minimum | Customer related intangible assets
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life		11 years
Minimum | Patents and other technology-based intangible assets
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life		6 years
Minimum | Tradenames and other amortizable intangible assets
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life		4 years
Minimum | Software and software development costs
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			3 years
Maximum | Customer related intangible assets
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life		19 years
Maximum | Patents and other technology-based intangible assets
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life		10 years
Maximum | Tradenames and other amortizable intangible assets
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life		16 years
Maximum | Software and software development costs
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years
Medical equipment used in rental arrangements
Accounting Policies [Line Items]
Depreciation expense		$ 25	$ 32	$ 28
Buildings and leasehold improvements | Minimum
Accounting Policies [Line Items]
Property, plant and equipment, useful life		10 years
Buildings and leasehold improvements | Minimum | Majority
Accounting Policies [Line Items]
Property, plant and equipment, useful life		20 years
Buildings and leasehold improvements | Maximum
Accounting Policies [Line Items]
Property, plant and equipment, useful life		40 years
Buildings and leasehold improvements | Maximum | Majority
Accounting Policies [Line Items]
Property, plant and equipment, useful life		40 years
Machinery and equipment | Minimum
Accounting Policies [Line Items]
Property, plant and equipment, useful life		3 years
Machinery and equipment | Minimum | Majority
Accounting Policies [Line Items]
Property, plant and equipment, useful life		5 years
Machinery and equipment | Maximum
Accounting Policies [Line Items]
Property, plant and equipment, useful life		15 years
Machinery and equipment | Maximum | Majority
Accounting Policies [Line Items]
Property, plant and equipment, useful life		10 years

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract with customer, liability, revenue recognized	$ 550	$ 540	$ 540
Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]	Total net sales	Total net sales
Operating lease, lease income	$ 600	$ 616	$ 603
One Customer | Accounts Receivable | Customer Concentration Risk
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Concentration risk, percentage		10%

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill Balance by Business Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Beginning balance	$ 6,535	$ 6,434
Divestiture		(4)
Translation impact	(158)	105
Ending balance	6,377	6,535
MedSurg
Goodwill [Roll Forward]
Beginning balance	3,685	3,606
Divestiture		0
Translation impact	(88)	79
Ending balance	3,597	3,685
Dental Solutions
Goodwill [Roll Forward]
Beginning balance	458	452
Divestiture		(4)
Translation impact	(19)	10
Ending balance	439	458
Health Information Systems
Goodwill [Roll Forward]
Beginning balance	873	871
Divestiture		0
Translation impact	(2)	2
Ending balance	871	873
Purification and Filtration
Goodwill [Roll Forward]
Beginning balance	1,519	1,505
Divestiture		0
Translation impact	(49)	14
Ending balance	$ 1,470	$ 1,519

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Narrative (Details) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Line Items]
Goodwill, acquired during period		$ 0	$ 0
Goodwill, written off related to sale of business unit			$ 4,000,000
Discontinued Operations, Disposed of by Sale | Assets Associated with Dental Local Anesthetic Business
Goodwill [Line Items]
Proceeds from sale of productive assets	$ 60,000,000
Gain (loss) on disposition of assets	56,000,000
Goodwill, written off related to sale of business unit	$ 4,000,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Total gross carrying amount	$ 5,344	$ 5,336
Total accumulated amortization	(2,800)	(2,459)
Total finite-lived intangible assets — net	2,544	2,877
Indefinite lived intangible assets	0	25
Intangible assets — net	2,544	2,902
Customer related intangible assets
Finite-Lived Intangible Assets [Line Items]
Total gross carrying amount	2,720	2,734
Total accumulated amortization	(1,208)	(1,081)
Patents and other technology-based intangible assets
Finite-Lived Intangible Assets [Line Items]
Total gross carrying amount	1,895	1,897
Total accumulated amortization	(1,224)	(1,055)
Tradenames and other amortizable intangible assets
Finite-Lived Intangible Assets [Line Items]
Total gross carrying amount	729	705
Total accumulated amortization	$ (368)	$ (323)

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 349	$ 365	$ 373

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) $ in Millions	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 324
2026	319
2027	314
2028	309
2029	272
After 2029	$ 1,006

Other Current Liabilities (Deta

Other Current Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Other Liabilities Disclosure [Abstract]
Accrued compensation	$ 281	$ 209
Accrued taxes	122	106
Accrued rebates	146	206
Accrued interest	114	0
Other	378	156
Total other current liabilities	$ 1,041	$ 677

Property, Plant, and Equipmen_3

Property, Plant, and Equipment - Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 3,610	$ 3,338
Accumulated depreciation	(1,988)	(1,881)
Property, plant and equipment - net	1,622	1,457
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	956	937
Machinery and equipment
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	2,150	2,081
Construction in progress
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 504	$ 320

Property, Plant, and Equipmen_4

Property, Plant, and Equipment - Net - Schedule of Depreciation Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 181	$ 164	$ 177

Comprehensive Income Informat_3

Comprehensive Income Information - Schedule Changes in Accumulated Other Compressive Income (Loss) by Component (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 11,666	$ 11,742	$ 12,059
Other comprehensive income (loss), before tax:
Total other comprehensive income (loss), net of tax	(188)	124	(297)
Ending balance	2,959	11,666	11,742
Cumulative Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(347)	(504)	(173)
Other comprehensive income (loss), before tax:
Amounts before reclassifications	(239)	157	(331)
Amounts reclassified out	38	0	0
Total other comprehensive income (loss), before tax	(201)	157	(331)
Tax effect	(2)	0	0
Total other comprehensive income (loss), net of tax	(203)	157	(331)
Transfers from 3M, net of tax	0	0	0
Ending balance	(550)	(347)	(504)
Defined Benefit Pension
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	10	7	(27)
Other comprehensive income (loss), before tax:
Amounts before reclassifications	(44)	(50)	45
Amounts reclassified out	39	0	2
Total other comprehensive income (loss), before tax	(5)	(50)	47
Tax effect	0	17	(13)
Total other comprehensive income (loss), net of tax	(5)	(33)	34
Transfers from 3M, net of tax	(531)	36	0
Ending balance	(526)	10	7
Cash Flow Hedging
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0	0	0
Other comprehensive income (loss), before tax:
Amounts before reclassifications	24	0	0
Amounts reclassified out	2	0	0
Total other comprehensive income (loss), before tax	26	0	0
Tax effect	(6)	0	0
Total other comprehensive income (loss), net of tax	20	0	0
Transfers from 3M, net of tax	0	0	0
Ending balance	20	0	0
Total Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(337)	(497)	(200)
Other comprehensive income (loss), before tax:
Amounts before reclassifications	(259)	107	(286)
Amounts reclassified out	79	0	2
Total other comprehensive income (loss), before tax	(180)	107	(284)
Tax effect	(8)	17	(13)
Total other comprehensive income (loss), net of tax	(188)	124	(297)
Transfers from 3M, net of tax	(531)	36	0
Ending balance	$ (1,056)	$ (337)	$ (497)

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
United States	$ (47)	$ 1,221	$ 1,276
International	652	446	416
Income before income taxes	$ 605	$ 1,667	$ 1,692

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Currently payable
Federal	$ 112	$ 148	$ 355
State	25	44	53
International	145	271	82
Deferred
Federal	(134)	(8)	(127)
State	(11)	(9)	(8)
International	(10)	(125)	(6)
Total	$ 127	$ 321	$ 349

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Miscellaneous accruals	$ 42	$ 52
Accrued compensation	159	102
Net operating/capital loss carryforward	55	95
Disallowed interest carryforwards	14	0
Foreign tax credits	35	52
Advanced royalties	0	26
Research and experimentation capitalization	129	213
Lease liabilities	32	16
Other deferred tax assets	20	37
Gross deferred tax assets	486	593
Valuation allowance	(33)	(56)
Total deferred tax assets	453	537
Deferred tax liabilities:
Property, plant, and equipment	(78)	(108)
Intangible assets	(278)	(324)
Right-of-use assets	(33)	(16)
Total deferred tax liabilities	(389)	(448)
Net deferred tax asset (liability)	$ 64	$ 89

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Deferred tax assets, valuation allowance	$ 33	$ 56
Net operating/capital loss carryforward	55	$ 95
Tax credit carryforward, amount	$ 37
Effective income tax rate reconciliation, percent	20.90%	19.30%	20.60%
Increase (decrease) in effective income tax rate, percent	1.60%
Unrecognized tax benefits, interest and penalties expected to be liable for	$ 36	$ 40
Unrecognized tax benefits that would impact effective tax rate	141
Unrecognized tax benefits, income tax penalties and interest expense (benefit)	(1)	(7.5)	$ 3.9
Unrecognized tax benefits, tax penalties and interest accrued	5.3	$ 4.5
Undistributed earnings of foreign subsidiaries	$ 2,000

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
U.S. Statutory income tax rate	21%	21%	21%
State income taxes - net of federal benefit	1.80%	1.70%	2.10%
International income taxes - net	(7.00%)	(1.30%)	(1.70%)
Global Intangible Low Taxed Income (GILTI)	4.20%	0.80%	0.70%
Foreign Derived Intangible Income (FDII)	(3.30%)	(2.20%)	(2.50%)
U.S. research and development credit	(4.10%)	(1.20%)	(1.80%)
Reserves for tax contingencies	(1.40%)	(4.10%)	0.60%
Tax impact of legal entity restructuring	4.70%	2.30%	0%
Changes in valuation allowance	2.60%	1.40%	0.70%
Deferred rate change	0.90%	0.10%	(0.30%)
All other - net	1.50%	0.80%	1.80%
Effective income tax rate	20.90%	19.30%	20.60%

Income taxes - Schedule of Unre

Income taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]
Gross UTB Balance at January 1	$ 205	$ 307	$ 308
Additions based on tax positions related to the current year	4	22	18
Additions for tax positions of prior years	0	17	17
Additions related to recent acquisitions	0	0	0
Reductions for tax positions of prior years	(64)	(35)	(19)
Settlements	0	0	0
Reductions due to lapse of applicable statute of limitations	(8)	(74)	(10)
Reductions for amounts recorded to net parent investment	0	(32)	(7)
Gross UTB Balance at December 31	$ 137	$ 205	$ 307

Long-Term Debt and Short-Term_3

Long-Term Debt and Short-Term Borrowings - Narrative (Details)					1 Months Ended
	Mar. 07, 2024 USD ($)	Mar. 04, 2024 USD ($)	Feb. 27, 2024 USD ($) series	Feb. 16, 2024 USD ($)	Dec. 31, 2024 USD ($)	Aug. 31, 2024 USD ($)	Apr. 01, 2024 USD ($)	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Long-term debt					$ 8,010,000,000			$ 0
Short-term debt								$ 0
Retained cash target							$ 600,000,000
Commercial paper					0
Commercial Paper
Debt Instrument [Line Items]
Debt instrument, term		364 days
Line of credit facility, maximum borrowing capacity		$ 2,000,000,000
Senior Notes
Debt Instrument [Line Items]
Series of notes issued | series			6
Debt instrument, face amount			$ 6,900,000,000
Debt issuance costs			62,000,000
Senior Notes | Estimate of Fair Value Measurement
Debt Instrument [Line Items]
Long-term debt, fair value					7,800,000,000
Senior Notes | Reported Value Measurement
Debt Instrument [Line Items]
Long-term debt, fair value					7,800,000,000
5.45% Senior Notes Due 2027 | Senior Notes
Debt Instrument [Line Items]
Long-term debt					995,000,000
Debt instrument, face amount			$ 1,000,000,000
Interest rate, stated percentage			5.45%
Debt instrument, term			3 years
5.40% Senior Notes Due 2029 | Senior Notes
Debt Instrument [Line Items]
Long-term debt					1,487,000,000
Debt instrument, face amount			$ 1,500,000,000
Interest rate, stated percentage			5.40%
Debt instrument, term			5 years
5.45% Senior Notes Due 2031 | Senior Notes
Debt Instrument [Line Items]
Long-term debt					990,000,000
Debt instrument, face amount			$ 1,000,000,000
Interest rate, stated percentage			5.45%
Debt instrument, term			7 years
5.60% Senior Notes Due 2034 | Senior Notes
Debt Instrument [Line Items]
Long-term debt					1,636,000,000
Debt instrument, face amount			$ 1,650,000,000
Interest rate, stated percentage			5.60%
Debt instrument, term			10 years
5.90% Senior Notes Due 2054 | Senior Notes
Debt Instrument [Line Items]
Long-term debt					1,231,000,000
Debt instrument, face amount			$ 1,250,000,000
Interest rate, stated percentage			5.90%
Debt instrument, term			30 years
6.00% Senior Notes Due 2064 | Senior Notes
Debt Instrument [Line Items]
Long-term debt					492,000,000
Debt instrument, face amount			$ 500,000,000
Interest rate, stated percentage			6%
Debt instrument, term			40 years
Credit Facilities | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term				5 years
Line of credit facility, maximum borrowing capacity				$ 2,000,000,000
Long-term line of credit					0
Credit Facilities | Line of Credit | Term Loan Credit Facilities
Debt Instrument [Line Items]
Proceeds from long-term lines of credit	$ 1,480,000,000
Credit Facilities | Line of Credit | 18-Month Senior Term Loan Credit Facility
Debt Instrument [Line Items]
Long-term debt					200,000,000
Debt instrument, term				18 months
Line of credit facility, maximum borrowing capacity				$ 500,000,000
Repayment of debt					100,000,000	$ 200,000,000
Credit Facilities | Line of Credit | 3-Year Senior Term Loan Credit Facility
Debt Instrument [Line Items]
Long-term debt					$ 979,000,000
Debt instrument, term				3 years
Line of credit facility, maximum borrowing capacity				$ 1,000,000,000

Long-Term Debt and Short-Term_4

Long-Term Debt and Short-Term Borrowings - Schedule of Long-Term and Short-Term Debt (Details) - USD ($)	Feb. 27, 2024	Feb. 16, 2024	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total			$ 8,010,000,000	$ 0
Less: current portion of long-term debt			200,000,000
Long-term debt (excluding current portion)			7,810,000,000	$ 0
Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 6,900,000,000
Other borrowings
Debt Instrument [Line Items]
Total			$ 0
Credit Facilities | 18-Month Senior Term Loan Credit Facility | Line of Credit
Debt Instrument [Line Items]
Debt instrument, term		18 months
Effective Interest Rate			6.13%
Total			$ 200,000,000
Credit Facilities | 3-Year Senior Term Loan Credit Facility | Line of Credit
Debt Instrument [Line Items]
Debt instrument, term		3 years
Effective Interest Rate			6.13%
Total			$ 979,000,000
5.45% Senior Notes Due 2027 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, term	3 years
Debt instrument, face amount	$ 1,000,000,000
Interest rate, stated percentage	5.45%
Effective Interest Rate			5.40%
Total			$ 995,000,000
5.40% Senior Notes Due 2029 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, term	5 years
Debt instrument, face amount	$ 1,500,000,000
Interest rate, stated percentage	5.40%
Effective Interest Rate			5.39%
Total			$ 1,487,000,000
5.45% Senior Notes Due 2031 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, term	7 years
Debt instrument, face amount	$ 1,000,000,000
Interest rate, stated percentage	5.45%
Effective Interest Rate			5.45%
Total			$ 990,000,000
5.60% Senior Notes Due 2034 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, term	10 years
Debt instrument, face amount	$ 1,650,000,000
Interest rate, stated percentage	5.60%
Effective Interest Rate			5.63%
Total			$ 1,636,000,000
5.90% Senior Notes Due 2054 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, term	30 years
Debt instrument, face amount	$ 1,250,000,000
Interest rate, stated percentage	5.90%
Effective Interest Rate			6.05%
Total			$ 1,231,000,000
6.00% Senior Notes Due 2064 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, term	40 years
Debt instrument, face amount	$ 500,000,000
Interest rate, stated percentage	6%
Effective Interest Rate			6.17%
Total			$ 492,000,000

Long-Term Debt and Short-Term_5

Long-Term Debt and Short-Term Borrowings - Schedule of Maturities of Long-Term Debt (Details) $ in Millions	Dec. 31, 2024 USD ($)
Debt Disclosure [Abstract]
2025	$ 200
2026	0
2027	1,980
2028	0
2029	1,500
After 2029	4,400
Total	$ 8,080

Pension and Postretirement Be_3

Pension and Postretirement Benefit Plans - Narrative (Details) $ in Millions			12 Months Ended
	Jan. 01, 2009	Dec. 31, 2008	Dec. 31, 2025	Dec. 31, 2024 USD ($) plan country	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jan. 01, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, cost of employee participation				$ 5	$ 32	$ 56
Defined benefit plan, number of plans | plan				25
Defined benefit plan, number of countries included in coverage | country				14
Company contributions				$ 16	11	4
Estimated pension contributions for next fiscal year				18
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 132	$ 0	$ 0
Expected return on assets				7.85%	0%	0%
Company contributions				$ 1	$ 0
Postretirement Benefits | Private equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				21	0
Postretirement Benefits | Fixed-Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				55	0
Postretirement Benefits | Absolute Return Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				18	0
United States
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution, percent of employee's gross pay	5%	5%
Employer matching contribution, percent of match	100%
Employer matching contribution, percent of employer retirement income account cash contribution	3%
Expenses related to defined contribution plans				93
United States | Minimum
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution, percent of match		45%
United States | Maximum
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution, percent of match		60%
United States | Qualified and Non-qualified Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 1,785	$ 0	$ 0
Expected return on assets				7.75%	0%	0%
Actual rate of return on plan assets				3.20%
Company contributions				$ 3	$ 0
United States | Qualified and Non-qualified Pension Benefits | Forecast
Defined Benefit Plan Disclosure [Line Items]
Expected return on assets			7.25%
United States | Qualified and Non-qualified Pension Benefits | Global Equities
Defined Benefit Plan Disclosure [Line Items]
Asset allocation assumption for next fiscal year (as a percent)				13%
United States | Qualified and Non-qualified Pension Benefits | Private equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 283	0
Asset allocation assumption for next fiscal year (as a percent)				15%
United States | Qualified and Non-qualified Pension Benefits | Fixed-Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 736	0
Asset allocation assumption for next fiscal year (as a percent)				57%
United States | Qualified and Non-qualified Pension Benefits | Absolute Return Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 245	0
Asset allocation assumption for next fiscal year (as a percent)				15%
United States | Nonqualified Plan
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 0
United States | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Percentage increase in employer contributions, per year							1.50%	3%
International
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, number of plans | plan				13
Defined benefit plan, number of countries included in coverage | country				9
Expenses related to defined contribution plans				$ 24
International | Qualified and Non-qualified Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 471	$ 367	$ 9
Expected return on assets				4.69%	4.61%	6.53%
Company contributions				$ 16	$ 11
International | Qualified and Non-qualified Pension Benefits | Private equity
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				48	47
International | Qualified and Non-qualified Pension Benefits | Fixed-Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				243	225
International | Qualified and Non-qualified Pension Benefits | Absolute Return Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets				$ 36	$ 38

Pension and Postretirement Be_4

Pension and Postretirement Benefit Plans - Schedule of Components of Net Periodic Cost Recognized in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Change in plan assets
Company contributions	$ 16	$ 11	$ 4
Postretirement Benefits
Change in benefit obligation
Benefit obligation at beginning of year	0	0
Service cost	3	0	0
Interest cost	9	0	0
Participant contributions	0	0
Foreign exchange rate changes	0	0
Actuarial (gain) loss	(10)	0
Benefit payments	(11)	0
Settlements, curtailments, special termination benefits and other	(1)	0
Transfers from 3M	260	0
Benefit obligation at end of year	250	0	0
Change in plan assets
Fair value of plan assets at beginning of year	0	0
Actual return on plan assets	3	0
Company contributions	1	0
Participant contributions	0	0
Foreign exchange rate changes	0	0
Benefit payments	(11)	0
Settlements, curtailments, special termination benefits and other	(1)	0
Transfers from 3M	140	0
Fair value of plan assets at end of year	132	0	0
Funded status at end of year	(118)	0
United States | Qualified and Non-qualified Pension Benefits
Change in benefit obligation
Benefit obligation at beginning of year	0	0
Service cost	20	0	0
Interest cost	70	0	0
Participant contributions	0	0
Foreign exchange rate changes	0	0
Actuarial (gain) loss	(9)	0
Benefit payments	(96)	0
Settlements, curtailments, special termination benefits and other	(2)	0
Transfers from 3M	1,874	0
Benefit obligation at end of year	1,857	0	0
Change in plan assets
Fair value of plan assets at beginning of year	0	0
Actual return on plan assets	48	0
Company contributions	3	0
Participant contributions	0	0
Foreign exchange rate changes	0	0
Benefit payments	(96)	0
Settlements, curtailments, special termination benefits and other	(2)	0
Transfers from 3M	1,832	0
Fair value of plan assets at end of year	1,785	0	0
Funded status at end of year	(72)	0
International | Qualified and Non-qualified Pension Benefits
Change in benefit obligation
Benefit obligation at beginning of year	519	105
Service cost	18	5	6
Interest cost	19	7	2
Participant contributions	1	0
Foreign exchange rate changes	(36)	19
Actuarial (gain) loss	(4)	70
Benefit payments	(10)	(8)
Settlements, curtailments, special termination benefits and other	1	0
Transfers from 3M	103	321
Benefit obligation at end of year	611	519	105
Change in plan assets
Fair value of plan assets at beginning of year	367	9
Actual return on plan assets	15	21
Company contributions	16	11
Participant contributions	1	0
Foreign exchange rate changes	(28)	16
Benefit payments	(10)	(8)
Settlements, curtailments, special termination benefits and other	0	0
Transfers from 3M	110	318
Fair value of plan assets at end of year	471	367	$ 9
Funded status at end of year	$ (140)	$ (152)

Pension and Postretirement Be_5

Pension and Postretirement Benefit Plans - Schedule of Amounts Recognized in the Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Accrued benefit cost
Non-current liabilities	$ (350)	$ (166)
Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Other assets	0	0
Accrued benefit cost
Current liabilities	(2)	0
Non-current liabilities	(70)	0
Ending balance	(72)	0
Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Other assets	18	9
Accrued benefit cost
Current liabilities	(3)	(1)
Non-current liabilities	(155)	(160)
Ending balance	(140)	(152)
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Other assets	0	0
Accrued benefit cost
Current liabilities	(1)	0
Non-current liabilities	(117)	0
Ending balance	$ (118)	$ 0

Pension and Postretirement Be_6

Pension and Postretirement Benefit Plans -Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Net actuarial loss (gain)	$ 47	$ 0
Prior service cost (credit)	(15)	0
Ending balance	32	0
United States | Qualified and Non-qualified Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Net actuarial loss (gain)	658	0
Prior service cost (credit)	0	0
Ending balance	658	0
International | Qualified and Non-qualified Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Net actuarial loss (gain)	4	(11)
Prior service cost (credit)	0	0
Ending balance	$ 4	$ (11)

Pension and Postretirement Be_7

Pension and Postretirement Benefit Plans -Schedule of Accumulated Benefit Obligations (Details) - Qualified and Non-qualified Pension Benefits - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
United States
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 1,775	$ 0
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	22	0
Fair value of plan assets	0	0
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	1,857	0
Fair value of plan assets	1,785	0
International
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	558	460
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	405	398
Fair value of plan assets	285	294
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	452	476
Fair value of plan assets	$ 294	$ 316

Pension and Postretirement Be_8

Pension and Postretirement Benefit Plans - Components of Net Periodic Benefit Cost and Other Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Postretirement Benefits
Operating expense
Service cost	$ 3	$ 0	$ 0
Non-operating expense
Interest cost	9	0	0
Expected return on plan assets	(7)	0	0
Amortization of prior service benefit	(3)	0	0
Amortization of net actuarial loss	3	0	0
Settlements, curtailments, special termination benefits and other	0	0	0
Total non-operating expense (benefit)	2	0	0
Total net periodic benefit cost (benefit)	5	0	0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss
Amortization of transition asset	0	0	0
Amortization of prior service benefit	3	0	0
Net actuarial (gain) loss	(6)	0	0
Amortization of net actuarial loss	(3)	0	0
Foreign currency	0	0	0
Settlements, curtailments, special termination benefits and other	0	0	0
Total recognized in other comprehensive (income) loss	(6)	0	0
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	(1)	0	0
United States | Qualified and Non-qualified Pension Benefits
Operating expense
Service cost	20	0	0
Non-operating expense
Interest cost	70	0	0
Expected return on plan assets	(103)	0	0
Amortization of prior service benefit	(2)	0	0
Amortization of net actuarial loss	40	0	0
Settlements, curtailments, special termination benefits and other	1	0	0
Total non-operating expense (benefit)	6	0	0
Total net periodic benefit cost (benefit)	26	0	0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss
Amortization of transition asset	0	0	0
Amortization of prior service benefit	2	0	0
Net actuarial (gain) loss	46	0	0
Amortization of net actuarial loss	(40)	0	0
Foreign currency	0	0	0
Settlements, curtailments, special termination benefits and other	(1)	0	0
Total recognized in other comprehensive (income) loss	7	0	0
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	33	0	0
International | Qualified and Non-qualified Pension Benefits
Operating expense
Service cost	18	5	6
Non-operating expense
Interest cost	19	7	2
Expected return on plan assets	(20)	(3)	(1)
Amortization of prior service benefit	0	0	0
Amortization of net actuarial loss	0	0	0
Settlements, curtailments, special termination benefits and other	1	0	2
Total non-operating expense (benefit)	0	4	3
Total net periodic benefit cost (benefit)	18	9	9
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss
Amortization of transition asset	0	0	(1)
Amortization of prior service benefit	0	0	0
Net actuarial (gain) loss	1	52	(43)
Amortization of net actuarial loss	0	1	(1)
Foreign currency	0	(2)	(2)
Settlements, curtailments, special termination benefits and other	0	(1)	0
Total recognized in other comprehensive (income) loss	1	50	(47)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	$ 19	$ 59	$ (38)

Pension and Postretirement Be_9

Pension and Postretirement Benefit Plans - Schedule of Weighted Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	5.64%	0%	0%
Compensation rate increase	3.77%	0%	0%
Discount rate - service cost	5.31%	0%	0%
Discount rate - interest cost	5.20%	0%	0%
Expected return on assets	7.75%	0%	0%
Compensation rate increase	3.77%	0%	0%
Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	3.54%	3.30%	4.59%
Compensation rate increase	2.88%	2.90%	3.22%
Discount rate - service cost	3.43%	4.88%	2.18%
Discount rate - interest cost	3.37%	5.24%	4.53%
Expected return on assets	4.69%	4.61%	6.53%
Compensation rate increase	2.89%	2.89%	3%
Postretirement Benefits
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	5.60%	0%	0%
Discount rate - service cost	5.30%	0%	0%
Discount rate - interest cost	5.14%	0%	0%
Expected return on assets	7.85%	0%	0%

Pension and Postretirement B_10

Pension and Postretirement Benefit Plans - Schedule of Estimated Pension and Postretirement Benefit Payments (Details) $ in Millions	Dec. 31, 2024 USD ($)
Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
2025 Benefit payments	$ 164
2026 Benefit payments	159
2027 Benefit payments	157
2028 Benefit payments	156
2029 Benefit payments	154
Next five years	737
Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
2025 Benefit payments	23
2026 Benefit payments	22
2027 Benefit payments	24
2028 Benefit payments	26
2029 Benefit payments	30
Next five years	160
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
2025 Benefit payments	20
2026 Benefit payments	21
2027 Benefit payments	21
2028 Benefit payments	22
2029 Benefit payments	22
Next five years	$ 104

Pension and Postretirement B_11

Pension and Postretirement Benefit Plans - Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 1,785	$ 0	$ 0
Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	471	367	9
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	132	0	$ 0
Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,777	0
Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	383	366
Defined Benefit Plan, Assets Before Other Items | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	132	0
Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	333	0
Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	2
Cash and cash equivalents | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	0
Equities | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	180	0
Equities | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	53	54
Equities | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13	0
Fixed income | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	736	0
Fixed income | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	243	225
Fixed income | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	55	0
Absolute return | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	245	0
Absolute return | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	36	38
Absolute return | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18	0
Private equity | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	283	0
Private equity | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	48	47
Private equity | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	21	0
Other items to reconcile to fair value of plan assets | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	0
Other items to reconcile to fair value of plan assets | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	88	1
Other items to reconcile to fair value of plan assets | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Level 1 | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	548	0
Level 1 | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	15
Level 1 | Defined Benefit Plan, Assets Before Other Items | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	41	0
Level 1 | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	333	0
Level 1 | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	2
Level 1 | Cash and cash equivalents | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	0
Level 1 | Equities | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	180	0
Level 1 | Equities | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5	7
Level 1 | Equities | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13	0
Level 1 | Fixed income | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35	0
Level 1 | Fixed income | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	6
Level 1 | Fixed income | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	0
Level 1 | Absolute return | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | Absolute return | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | Absolute return | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | Private equity | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | Private equity | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | Private equity | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	701	0
Level 2 | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	246	211
Level 2 | Defined Benefit Plan, Assets Before Other Items | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	52	0
Level 2 | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Cash and cash equivalents | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Equities | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Equities | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29	23
Level 2 | Equities | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Fixed income | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	701	0
Level 2 | Fixed income | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	217	188
Level 2 | Fixed income | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	52	0
Level 2 | Absolute return | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Absolute return | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Absolute return | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Private equity | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Private equity | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Private equity | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33	28
Level 3 | Defined Benefit Plan, Assets Before Other Items | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Cash and cash equivalents | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Equities | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Equities | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Equities | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Fixed income | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Fixed income | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Fixed income | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Absolute return | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Absolute return | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33	28
Level 3 | Absolute return | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Private equity | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Private equity | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Private equity | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	528	0
Fair Value Measured at Net Asset Value Per Share | Defined Benefit Plan, Assets Before Other Items | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	90	112
Fair Value Measured at Net Asset Value Per Share | Defined Benefit Plan, Assets Before Other Items | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	39	0
Fair Value Measured at Net Asset Value Per Share | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Cash and cash equivalents | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Cash and cash equivalents | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Equities | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Equities | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	19	24
Fair Value Measured at Net Asset Value Per Share | Equities | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Fixed income | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Fixed income | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	20	31
Fair Value Measured at Net Asset Value Per Share | Fixed income | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share | Absolute return | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	245	0
Fair Value Measured at Net Asset Value Per Share | Absolute return | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	10
Fair Value Measured at Net Asset Value Per Share | Absolute return | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18	0
Fair Value Measured at Net Asset Value Per Share | Private equity | Qualified and Non-qualified Pension Benefits | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	283	0
Fair Value Measured at Net Asset Value Per Share | Private equity | Qualified and Non-qualified Pension Benefits | International
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	48	47
Fair Value Measured at Net Asset Value Per Share | Private equity | Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 21	$ 0

Derivatives - Narrative (Detail

Derivatives - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Maximum length of time hedged in cash flow hedge	36 months
Gross Notional Amount	$ 1,289	$ 0
Year-on-year foreign currency transaction effects, including hedging impact, increase (decrease) impact on pre-tax (loss) income	(23)	9	$ 27
Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gross Notional Amount	892	0
Designated as Hedging Instrument | Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gross Notional Amount	380	$ 0
Cash Flow Hedging | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Accumulated other comprehensive income (loss), unrealized gain (loss) on cash flow hedges	20
After-tax net unrealized gain (loss) anticipated to be reclassified from AOCI to the income statement within next twelve months	13
Net Investment Hedging | Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gross Notional Amount	$ 380

Derivatives - Schedule of Gains

Derivatives - Schedule of Gains (Loss) on Derivative Instruments Designated as Hedges (Details) - Designated as Hedging Instrument - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Foreign currency forward contracts | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency forward contracts	$ 26	$ 0	$ 0
Cross-currency swaps | Net Investment Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Cross-currency swaps	$ 10	$ 0	$ 0

Derivatives - Schedule of Locat

Derivatives - Schedule of Location and Fair Value of Derivative Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Gross Notional Amount	$ 1,289	$ 0
Assets Fair Value Amount	33	0
Liabilities Fair Value Amount	0	0
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross Notional Amount	892	0
Assets Fair Value Amount	33	0
Liabilities Fair Value Amount	0	0
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross Notional Amount	397	0
Assets Fair Value Amount	0	0
Liabilities Fair Value Amount	0	0
Foreign Exchange Contract, One | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross Notional Amount	355	0
Foreign Exchange Contract, Two | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross Notional Amount	157	0
Foreign currency forward contracts | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross Notional Amount	397	0
Cross-currency swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross Notional Amount	380	0
Other Current Assets | Foreign Exchange Contract, One | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets Fair Value Amount	17	0
Other Current Assets | Foreign currency forward contracts | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets Fair Value Amount	0	0
Other Noncurrent Assets | Foreign Exchange Contract, Two | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets Fair Value Amount	6	0
Other Noncurrent Assets | Cross-currency swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets Fair Value Amount	10	0
Other Current Liabilities | Foreign Exchange Contract, One | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities Fair Value Amount	0	0
Other Current Liabilities | Foreign currency forward contracts | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities Fair Value Amount	0	0
Other Noncurrent Liabilities | Foreign Exchange Contract, Two | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities Fair Value Amount	0	0
Other Noncurrent Liabilities | Cross-currency swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities Fair Value Amount	$ 0	$ 0

Commitment and Contingencies (D

Commitment and Contingencies (Details) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2022 case	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($) case lawsuit classAction	Dec. 31, 2023 USD ($)	Dec. 31, 2019 case	Dec. 31, 2011 quiTamAction	Dec. 31, 2008 employee quiTamAction
Loss Contingencies [Line Items]
Legal charges (recoveries) in period			$ 8	$ 9
Payments for legal settlements		$ 6
Loss contingency accrual			25	$ 23
Guarantor obligations, current carrying value			$ 40
3M | Bair Hugger Patient Warming Systems Litigation
Loss Contingencies [Line Items]
Total lawsuits to date | lawsuit			7,800
Number of putative class actions | classAction			1
Number of pending/ongoing cases | case			6
Number of cases dismissed | case					61
3M | Federal False Claims Act/Qui Tam Litigation
Loss Contingencies [Line Items]
Number of pending/ongoing cases | quiTamAction						2	2
Number of cases dismissed | case	1
Number of employees who filed qui tam actions | employee							2

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease cost	$ 75	$ 28	$ 32

Leases - Balance Sheet Informat

Leases - Balance Sheet Information (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease right of use assets	$ 176	$ 98
Current operating lease liabilities	87	29
Noncurrent operating lease liabilities	86	69
Total operating lease liabilities	$ 173	$ 98
Weighted average remaining lease term (in years):	2 years 10 months 24 days	4 years 3 months 18 days
Weighted average discount rate:	4.20%	2.90%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other current liabilities, Other liabilities	Other current liabilities, Other liabilities

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities:	$ 76	$ 29	$ 31
Right of use assets obtained in exchange for operating lease liabilities:	$ 148	$ 37	$ 14

Leases - Maturities of Operatin

Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2025	$ 89
2026	44
2027	22
2028	10
2029	4
After 2029	7
Total expected lease payments	176
Less: Amounts representing interest	(3)
Total operating lease liabilities	$ 173	$ 98

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 62

Restructuring - Restructuring C

Restructuring - Restructuring Charges within Income Statement (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]
Total operating income impact	$ 62
Cost of sales
Restructuring Cost and Reserve [Line Items]
Total operating income impact	$ 17
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of sales
Cost of software and rentals
Restructuring Cost and Reserve [Line Items]
Total operating income impact	$ 2
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of sales
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Total operating income impact	$ 36
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses
Research and development expenses
Restructuring Cost and Reserve [Line Items]
Total operating income impact	$ 7
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Research and development expenses

Restructuring - Cash and Non-Ca

Restructuring - Cash and Non-Cash Impacts (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]
Expense incurred in 2024	$ 62
Non-cash changes	(8)
Cash payments	(1)
Accrued liabilities as of December 31, 2024	53
Employee Termination Benefits
Restructuring Cost and Reserve [Line Items]
Expense incurred in 2024	46
Non-cash changes	0
Cash payments	(1)
Accrued liabilities as of December 31, 2024	45
Asset-Related and Other
Restructuring Cost and Reserve [Line Items]
Expense incurred in 2024	16
Non-cash changes	(8)
Cash payments	0
Accrued liabilities as of December 31, 2024	$ 8

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares	12 Months Ended
	Dec. 31, 2024	Apr. 01, 2024	Mar. 31, 2024	Dec. 31, 2023
Earnings Per Share [Abstract]
Common stock issued (in shares)	172,785,606	172,709,505	0	0
Common stock outstanding (in shares)	172,785,606	172,709,505	0	0
Antidilutive securities excluded from computation of earnings per share (in shares)	4,000,000

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Computation of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Numerator:
Net income	$ 479	$ 1,346	$ 1,343
Denominator:
Weighted average common shares outstanding – basic (in shares)	173.2	172.7	172.7
Dilution associated with stock-based compensation plans (in shares)	0.5	0	0
Weighted average common shares outstanding – diluted (in shares)	173.7	172.7	172.7
Basic earnings per share (in dollars per share)	$ 2.77	$ 7.79	$ 7.78
Diluted earnings per share (in dollars per share)	$ 2.76	$ 7.79	$ 7.78

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions		9 Months Ended	12 Months Ended
	Apr. 01, 2024	Dec. 31, 2024	Dec. 31, 2024	Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Retirement eligibility for employees, minimum years of service required (in years)			10 years
Employee Stock Option
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (in years)			3 years
Expiration of annual grants (in years)			10 years
Granted (in shares)		0
Compensation expense yet to be recognized		$ 1.5	$ 1.5
Expense recognition period (in months)			10 months
Restricted Stock Units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Excluding options, compensation cost not yet recognized		107	$ 107
Expense recognition period (in months)			22 months
Restricted Stock Units | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (in years)			1 year
Restricted Stock Units | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (in years)			3 years
Performance Shares Units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Performance target period			3 years
Excluding options, compensation cost not yet recognized		37	$ 37
Expense recognition period (in months)			24 months
Performance Shares Units | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award granted based on performance, percentage			0%
Performance Shares Units | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award granted based on performance, percentage			200%
Solventum 2024 Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment arrangement, plan modification, incremental cost	$ 22	20
Unvested awards		$ 2	$ 2
Solventum 2024 Plan | Spinoff
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum shares issued				13,000,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses	$ 112	$ 39	$ 37
Income tax benefits	(18)	(9)	(9)
Stock-based compensation expenses, net of tax	94	30	28
Cost of sales
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses	14	8	8
Selling, general and administrative expenses
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses	82	23	20
Research and development expenses
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses	$ 16	$ 8	$ 9

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Employee Stock Option - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Dec. 31, 2024	Mar. 31, 2024
Number of Options
Beginning balance (in shares)	3,991	4,073
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	(35)
Expired (in shares)	(47)
Ending balance (in shares)	3,991
Exercisable (in shares)	3,571
Expected to vest (in shares)	419
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 106.45
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	86.46
Expired (in dollars per share)	106.52
Ending balance (in dollars per share)	106.63
Exercisable (in dollars per share)	108.56
Expected to vest (in dollars per share)	$ 90.30
Weighted Average Remaining Contractual Term (months)
Outstanding (in months)	55 months
Exercisable (in months)	51 months
Expected to vest (in months)	90 months
Aggregate Intrinsic Value (millions)
Outstanding	$ 0
Exercisable	0
Expected to vest	$ 0

Stock-Based Compensation - Summ

Stock-Based Compensation - Summarizes the RSU Activity (Details) - Restricted Stock Units - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Number of Shares
Beginning balance (in shares)	1,304
Granted (in shares)	2,305
Vested (in shares)	(136)
Forfeited (in shares)	(136)
Ending balance (in shares)	3,337	3,337
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 76.93
Granted (in dollars per share)	62.77	$ 62.77	$ 0	$ 0
Vested (in dollars per share)	67.12
Forfeited (in dollars per share)	68.54
Ending balance (in dollars per share)	$ 67.89	$ 67.89

Stock-Based Compensation - Equi

Stock-Based Compensation - Equity-based Awards (Details) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value of restricted stock units (per unit) that were granted (in dollars per share)	$ 62.77	$ 62.77	$ 0	$ 0
Total fair value of restricted stock units that vested		$ 9	$ 0	$ 0

Related Parties - Schedule of P

Related Parties - Schedule of Parent's Expense Allocations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Selling, general and administrative expenses	$ 2,782	$ 2,243	$ 2,235
Research and development expenses	775	758	767
Cost of product
Related Party Transaction [Line Items]
Cost of sales	3,172	3,023	2,953
Cost of software and rentals
Related Party Transaction [Line Items]
Cost of sales	489	481	482
Related Party
Related Party Transaction [Line Items]
Cost of sales	37
Related Party | Prior To Spin-Off
Related Party Transaction [Line Items]
Selling, general and administrative expenses	177	678	617
Research and development expenses	28	86	87
Total operating expenses	220	853	778
Related Party | Prior To Spin-Off | Cost of product
Related Party Transaction [Line Items]
Cost of sales	15	89	74
Related Party | Prior To Spin-Off | Cost of software and rentals
Related Party Transaction [Line Items]
Cost of sales	$ 0	$ 0	$ 0

Related Parties - Narrative (De

Related Parties - Narrative (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Net transfers to 3M		$ 9,102	$ 1,546	$ 1,363
Total net sales		$ 8,254	$ 8,197	$ 8,130
Related Party
Related Party Transaction [Line Items]
Net transfers to 3M	$ 1,100
Separation and distribution agreement, transition services, term		2 years
Separation and distribution agreement, transition distribution services, extension term		1 year
Separation and distribution agreement, transition manufacturing contract		3 years
Separation and distribution agreement, real estate license terms		2 years
Separation and distribution agreement, master supply, terms		3 years
Total net sales		$ 50
Cost of sales		37
Non-current amounts due to related parties	$ 170	170
Related Party | Transition Agreement Services
Related Party Transaction [Line Items]
Operating expenses		369
Related Party | Master Supply Agreements
Related Party Transaction [Line Items]
Cost of sales		$ 128
Related Party | Minimum
Related Party Transaction [Line Items]
Separation and distribution agreement, individual services, terms		18 months
Related Party | Maximum
Related Party Transaction [Line Items]
Separation and distribution agreement, individual services, terms		36 months

Related Parties - Condensed Con

Related Parties - Condensed Consolidated Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Net sales of product	$ 8,254	$ 8,197	$ 8,130
Selling, general and administrative expenses	2,782	2,243	2,235
Research and development expenses	775	758	767
Related Party
Related Party Transaction [Line Items]
Net sales of product	50
Cost of product	37
Related Party | After Spin-Off
Related Party Transaction [Line Items]
Selling, general and administrative expenses	202	0
Research and development expenses	8	0
Cost of product
Related Party Transaction [Line Items]
Net sales of product	6,348	6,296	6,300
Cost of product	3,172	3,023	$ 2,953
Cost of product | Related Party | After Spin-Off
Related Party Transaction [Line Items]
Net sales of product	50	0
Cost of product	$ 357	$ 0

Related Parties - Schedule of R

Related Parties - Schedule of Reconciliation of Net Transfers to Parent (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Net transfers to 3M on the consolidated changes in equity		$ (9,102)	$ (1,546)	$ (1,363)
Stock compensation expense		(112)	(39)	(37)
Net transfers to 3M on the consolidated statements of cash flows		(8,251)	(1,553)	(1,456)
Related Party
Related Party Transaction [Line Items]
Net transfers to 3M on the consolidated changes in equity	$ (1,100)
Stock compensation expense		(4)	(39)	(37)
Multiemployer pension expense		(5)	(32)	(56)
Net balances transferred from 3M		329	100	0
Net transfers to 3M on the consolidated statements of cash flows		(8,251)	(1,553)	(1,456)
Net Parent Investment
Related Party Transaction [Line Items]
Net transfers to 3M on the consolidated changes in equity		(8,571)	(1,582)	(1,363)
Net Parent Investment | Related Party
Related Party Transaction [Line Items]
Net transfers to 3M on the consolidated changes in equity		$ (8,571)	$ (1,582)	$ (1,363)

Business Segments - Narrative (

Business Segments - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 operatingSegment
Segment Reporting [Abstract]
Number of operating segments	4

Business Segments - Schedule of

Business Segments - Schedule of Business Segment Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total net sales	$ 8,254	$ 8,197	$ 8,130
Operating Income	1,036	1,692	1,693
Interest expense, net	367	0	0
Other expense/(income), net	64	25	1
Income before income taxes	605	1,667	1,692
Operating Segments
Segment Reporting Information [Line Items]
Operating Income	1,762	2,134	2,034
Corporate and Unallocated
Segment Reporting Information [Line Items]
Total net sales	59	0	0
Operating Income	(726)	(442)	(341)
Amortization expense	(349)	(365)	(373)
Other corporate and unallocated	(377)	(77)	32
MedSurg | Operating Segments
Segment Reporting Information [Line Items]
Total net sales	4,637	4,632	4,585
Cost of sales	2,151	2,087	2,085
Operating expenses	1,600	1,438	1,439
Operating Income	887	1,107	1,061
Depreciation expense	123	128	144
Dental Solutions | Operating Segments
Segment Reporting Information [Line Items]
Total net sales	1,295	1,329	1,327
Cost of sales	425	455	471
Operating expenses	519	432	419
Operating Income	350	442	437
Depreciation expense	28	23	22
Health Information Systems | Operating Segments
Segment Reporting Information [Line Items]
Total net sales	1,306	1,285	1,227
Cost of sales	361	358	361
Operating expenses	513	504	507
Operating Income	431	423	359
Depreciation expense	5	4	3
Purification and Filtration | Operating Segments
Segment Reporting Information [Line Items]
Total net sales	956	951	991
Cost of sales	571	554	578
Operating expenses	291	235	236
Operating Income	94	162	177
Depreciation expense	$ 40	$ 37	$ 35

Business Segments - Sale by Geo

Business Segments - Sale by Geographic Area (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 8,254	$ 8,197	$ 8,130
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	4,749	4,603	4,450
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 3,505	$ 3,594	$ 3,680

Business Segments - Long-lived

Business Segments - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1,859	$ 1,620
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	1,046	875
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	457	477
Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 356	$ 268

Subsequent Events (Details)

Subsequent Events (Details) $ in Billions	Feb. 25, 2025 USD ($)
Subsequent Event | Purification and Filtration Business | Discontinued Operations, Held-for-Sale
Subsequent Event [Line Items]
Disposal group, including discontinued operation, consideration	$ 4.1